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The coordination of tissue function is mediated by gap junctions (GJs) that enable direct cell-cell transfer of metabolic and electric
signals. GJs are formed by connexin (Cx) proteins of which Cx43 is most widespread in the human body. Beyond its role in
direct intercellular communication, Cx43 also forms nonjunctional hemichannels (HCs) in the plasma membrane that mediate
the release of paracrine signaling molecules in the extracellular environment. Both HC and GJ channel function are regulated by
protein-protein interactions and posttranslational modifications that predominantly take place in the C-terminal domain of Cx43.
Matrix metalloproteases (MMPs) are a major group of zinc-dependent proteases, known to regulate not only extracellular matrix
remodeling, but also processing of intracellular proteins. Together with Cx43 channels, both GJs and HCs, MMPs contribute to
acute inflammation and a small number of studies reports on an MMP-Cx43 link. Here, we build further on these reports and
present a novel hypothesis that describes proteolytic cleavage of the Cx43 C-terminal domain by MMPs and explores possibilities
of how such cleavage events may affect Cx43 channel function. Finally, we set out how aberrant channel function resulting from
cleavage can contribute to the acute inflammatory response during tissue injury.
1. General Aspects of Matrix-Metalloproteases
and Their Role in Inflammation
Metzincinmatrix-metalloproteases (MMPs) comprise a large
family of endopeptidases of which today, 24 distinct genes
have been identified in man (only 23 have been identified in
mouse) [1].Theprefix “metallo-” refers to the reliance of these
endopeptidases on zinc ions to perform hydrolysis of their
respective protein substrates. MMPs are best known for their
actions in remodeling of extracellular matrix (ECM) proteins
and typical classification of the MMPs is based on their ECM
substrate, their primary structure, and their subcellular local-
ization. Later, MMPs were named according to their historic
order of discovery. Groups ofMMPs thus include the collage-
nases (MMP-1, MMP-8, and MMP-13), stromelysins (MMP-
3 and MMP-10), stromelysin-like MMPs (MMP-11 and
MMP-12), matrilysins (MMP-7 and MMP-26), membrane-
type MMPs (MT-MMP-1 to MT-MMP-6), GPI-type MMPs
(MMP-17 and MMP-25), and, probably the best known,
gelatinases (MMP-2 and MMP-9) [2–4]. Research dedicated
to identifying MMP targets has however uncovered that in
fact the prefix “matrix” is far from complete as the MMP
substrate repertoire is much more diverse and also includes
growth factors, hormones, cytokines, and chemokines. Even
more, MMPs are now known to also cleave intracellular tar-
gets (see later) [2, 3]. This multitude of target proteins grants
MMPs involvement in a wide array of cellular functions. As
such, they contribute to cellular differentiation and migra-
tion, regulation of growth factor activity, and cell survival as
well as apoptosis, angiogenesis, and inflammation [1].
MMP activity is controlled at three levels: (i) tran-
scription; (ii) proenzyme activation, and (iii) inhibition by
endogenous proteins, most notably the “tissue inhibitors
of metalloproteases” (TIMPs; TIMP-1 to TIMP-4). MMPs
are synthesized as zymogens that are activated while being
located intracellularly (see further), bound to the plasma
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membrane, or after secretion in the extracellular envi-
ronment, most commonly by removal of their propeptide
domain. A cysteine residue in the propeptide domain inter-
acts with the catalytic zinc ion, thereby preventing protease
activity until the propeptide domain is removed. The disso-
ciation of this cysteine-Zn2+ interaction (“cysteine switch”)
is a critical step in the activation of all MMPs. The third and
fourth MMP protein domains are a linker region of variable
length and a hemopexin domain that confers substrate
specificity [2, 5]. TIMPs bind to the catalytic subunit ofMMPs
and inhibit them with a 1 : 1 stoichiometry (note though
that there are just four TIMPs for over twenty MMPs) and
the protease-antiprotease paradigm states that the net MMP
proteolytic activity is the difference of total active MMPs
minus the total TIMP activity [6]. Internalization, protease
activity, posttranslational modifications (S-nitrosylation, gly-
cosylation, oxidation, and alkylation), compartmentalization,
and availability of substrates add additional levels of MMP
activity control [1, 3].
MMPs are implicated in many physiological as well as
pathological conditions, but we here focus on their role in
inflammation. The inflammatory response is characterized
by a cascade of molecular events including the secretion of
cytokines, chemokines, and proteases by the damaged tissue
as well as by infiltrating mast cells and neutrophils which are
the sentinels responsible for detecting tissue damage or infec-
tion. This acute response subsequently promotes invasion
of leukocytes from the blood side into the inflamed tissue,
giving rise to a more chronic inflammatory state. In nearly
every organ or tissue system, MMPs are involved at several
levels of the inflammatory cascade. For instance, efficient
migration and extravasation of leukocytes along chemotactic
gradients to sites of infection are important for establishing
effective immunity andMMPs have been shown to contribute
to these functions. MMPs aid in establishing a chemotactic
signal for recruitment of leukocytes and at the same time
degrade ECM and junctional proteins, promoting leukocyte
infiltration. Chemokines are immobilized mostly on the
ECM or cell surface by binding to glycosaminoglycans and
MMPs might contribute to the liberation of these molecules,
delivering soluble effectors in the extracellular environment
[8]. Paracellular movement of leukocytes is impeded by
tight junctions and adherens junctions that occlude the
intercellular cleft. Occludin and zonula occludens-1 (ZO-1),
important components of the intercellular tight junctional
complex, have been identified as substrates of MMPs [9–
11]. In addition, vascular endothelium- (VE-) cadherin and
E-cadherin, major components of the adherens junction,
are known to be cleaved by MMP-7 and MMP-9 [12–14].
Importantly, MMPs are derived from the injured tissue as
well as from the infiltrating immune cells. MMP-8 and
MMP-9 are, for instance, stored in intracellular granules in
neutrophils. Macrophages are on the other hand important
in attenuating the acute immune response. Here, MMPs
contribute by removing the chemotaxis of neutrophils and by
inhibiting T-cell proliferation and function [4, 5].
At a second level, MMPs regulate the availability and
activity of inflammatory mediators, including cytokines and
chemokines. Whereas the proinflammatory tumor necrosis
factor-alpha (TNF𝛼) is generally activated by MMPs, a dual
role has been proposed with respect to interleukin-1-beta
(IL1𝛽) activity [15, 16].Vice versa, several cytokines are impli-
cated in the (up)regulation of MMPs. As such, TNF𝛼, IL1𝛽,
and transforming growth factor-beta (TGF𝛽) are implicated
in the upregulation of MMP-1, MMP-3, and MMP-9 via the
nuclear factor kappa-B (NF𝜅B) transcription factor, thereby
creating a positive feedback loop [17–19].
Finally, MMPs can trigger a specialized form of pro-
grammed cell death termed anoikis that is induced by cells
detaching from the surrounding ECM by interrupting cell-
cell and cell-matrix interactions [20].
A thorough discussion of isolated MMPs’ contribution
to inflammation falls beyond the scope of this review but is
excellently reviewed by others [4, 21, 22]. There are however
some aspects that we would wish to highlight here. A first
and very relevant aspect of MMPs in view of this review is
the activation kinetics of MMPs. Some MMPs, for example,
MT-MMPs and the downstream MMP-2, are believed to
be constitutively active, although their activity can still be
enhanced in inflammatory conditions [23]. Oppositely, other
MMPs such as MMP-9 are only induced and activated under
conditions of immune activation and are normally associated
with activated leukocytes, macrophages, and endothelium
[2]. Being dependent on the presence of proinflammatory
cytokines and a cascade of cleavage events by upstream
proteases (other MMPs, plasmin), activation of MMPs is
considered to be a slightly delayed (nevertheless acute)
event in the inflammatory response [1, 23]. However, as we
will discuss later, removal of the prodomain is not always
required and MMPs may be acting at a faster time scale
in such conditions. Second, the mode of activation largely
determines the site of MMP activity. Being dependent on
membrane-bound MT1- and MT3-MMPs for its activation,
MMP-2, for example, is generally considered to be spatially
constrained, whereas other MMPs like MMP-9 are released
in the extracellular space and diffuse to more remote sites.
Therefore, secreted MMPs are presumed to cause more
widespread damage [23]. In addition, as outlined below,
MMPs are now also known to cleave intracellular substrates,
unlocking a new level of complexity with respect to their role
in inflammation. In the following sections we will discuss
their action on connexin (Cx) channel function. These
channels too have been identified as important contributors
to the inflammatory process (see later); however, only a small
number of papers suggested a link between Cxs and MMPs.
Their interaction at the functional level therefore remains
poorly understood. Here, we try to explain how an MMP-Cx
interaction may mechanistically alter channel function and
contribute to acute inflammation.
2. Connexin Channels:
Gap Junctions and Hemichannels
Cxs are a family of transmembrane proteins with molecular
weights (MW) varying from 26 to 60 kDa on which the cur-
rent nomenclature is based (e.g., Cx43 has aMWof∼43 kDa).
Cxs form two kinds of channels, namely, gap junctions (GJs)
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and hemichannels (HCs). GJs mediate the direct diffusion
of ions and molecules with MWs up to 1.5–2 kDa, including
inositol 1,4,5 trisphosphate, cyclic nucleotides, and energy
molecules such as glucose andATP [24], thereby contributing
to the coordination of cell function in several organs and
tissues. GJ channel-mediated intercellular communication
(GJIC) is, for instance, implicated in the communication
of electrical signals between cardiomyocytes, coordinating
cardiac pump function. GJIC between smooth muscle cells
coordinates, for example, bladder and uterus function [25,
26]. GJs also pass signalingmolecules tomediate the propaga-
tion of intercellular Ca2+ waves in various tissues and organs
[27], they provide metabolic coupling between liver cells or
astrocytes [28–30] and contribute to the exchange of bone
modulating molecules [31]. However, on the downside, GJs
also spread cell death signals to neighboring cells, thereby
contributing to tissue/organ damage in pathology [32]. Half
GJ channels that arise from the hexameric assembly of
different Cx subunits can be present in the plasmamembrane
both as GJ precursors, called connexons, or as nonjunctional,
functional channels, known as HCs. For a long time, it
was thought that the only reason for a HC to open was
related to their incorporation into a GJ channel. Uncon-
trolled HC opening was presumed to lead to membrane
depolarization and depletion of essential molecules from
the cytoplasm, ultimately resulting in cell dysfunction and
possibly cell death. The first evidence of functional HCs
arose from in vitro work using Cx46 expression in Xenopus
laevis oocytes, indicating that HC opening resulted not
only in dye uptake, but also in cell depolarization and cell
death [33]. Research over the past decades has however
identified numerous scenarios in which HCs are activated
to open, thereby contributing to paracrine signaling through
the release of ATP [34], glutamate [35], glutathione [36],
NAD+ [37], and prostaglandins [38, 39]. HC-mediated ATP
release, for instance, functions as a paracrine signal in the
propagation of intercellular Ca2+ waves [27, 40]. Evidence is
accruing that HCs may contribute to physiological functions
such as “center-surround” antagonism in the retina [37, 41],
osteogenesis [31, 42], regulation of vascular permeability
[43], central chemoreception [44], and atherosclerotic plaque
formation [45]. However, HCs also have an established role in
pathological conditions associated with inflammation which
has been particularly well-documented in the brain [46–54].
Finally, both HCs and GJs are important in the induction as
well as the propagation of cell death [55].
In this review we will focus on the actions of MMPs on
GJs and HCs formed by Cx43, which is ubiquitously present
in a large array of cells and tissues in the human body [56].
Furthermore, Cx43 is the isoform that has been characterized
in great detail in terms of intramolecular gating mechanisms
as well as its role in inflammation at the functional level.
3. MMPs’ Impact on Connexin Expression and
Channel Function
3.1. Intracellular Action of MMPs. The only paper thus far
indicating that Cx43 is a target for MMPs, more specifically
MMP-7, has documented cleavage of the intracellularly
located C-terminal domain [7]. Indeed, as outlined above,
MMP activity is not confined to the extracellular space and
substrates are much more diverse than just matrix proteins.
At present, intracellular targets such as intracellular matrix
proteins, enzymes, and molecular chaperones regulating
transcription and translation are well known to be part of
the MMP substrate repertoire. Multiple MMPs, including
MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-
13, MMP-26, and MT1,3-MMP, have been shown to process
intracellular proteins, indicating that intracellular activity of
MMPs is not confined to one particular class of MMPs [3].
MMP-3 is, for example, activated in dopaminergic neurons
by the apoptosis inducer BH4 and acts upstream of caspase-3,
indirectly contributing to the cleavage and activation of this
apoptotic mediator [57]. High throughput degradomics
has furthermore identified a myriad of intracellular matrix
proteins as substrates of MMP-9, many of which are linked
to different autoimmune diseases. Such data indicate
that MMP-9 may have an immune-regulatory function,
removing toxic molecules that are released upon cell death,
but also generating substrates for autoantigens [58]. Finally,
intracellular activity of MMP-2 has been confirmed in fast
twitch type II muscle fibers with protease activity being
dependent on physical exercise [59]; MMP-2’s specific role
is however unknown in these cells. In platelets, intracellular
activity ofMMP-2 contributes to platelet aggregation [60, 61].
Intracellular activation of MMPs may be achieved by
intracellular proteases that separate the prodomain from the
catalytic domain. The Golgi-associated prohormone conver-
tase furin, for instance, activates MMP-11 by cleavage at the
Arg-X-Arg-X-Lys-Arg sequence. This recognition motif has
also been identified in MT1-, MT2-, MT3-, MT4-, and MT5-
MMPs and in MMP-23, while the similar Arg-X-X-Arg and
Lys-X-X-Arg sequences have been found in all MMPs, except
MMP-7 and MMP-12 [2, 3]. Other candidate mechanisms
for intracellular proteolytic processing of MMPs include
serine proteases, caspases, upstream intracellularMMPs, and
autolytic cleavage [2, 3]. Trypsin-2 has, for instance, been
shown to activate MMP-9 inside intracellular vesicles of
epithelial cancer cells, thereby determining the aggressive
and invasive character of these cells [62]. Intracellular MMP
activation does not always require removal of the pro-
domain. Reactive oxygen (ROS, e.g., peroxynitrite) and nitro-
gen (RNS) species that reassociated with oxidative stress may
interact with the Cys-thiol group and disrupt the interaction
with Zn2+, leading to autocatalytic activation while the
full-length pro-MMP remains intact. S-nitrosylation and S-
glutathionylation have been shown to activateMMP-1,MMP-
2, MMP-8, and MMP-9 [2, 3, 63]. MMP-2, MMP-7, MMP-
8, and MMP-9 activity have been furthermore shown to
be dependent on ROS levels with low levels activating the
proteases and high levels preventing protease activity. At the
same time, ROS may also alter the structure and binding
affinity of TIMPs, resulting in lower affinity and dissociation
from the MMPs [64]. Alternatively, oxidative stress has been
shown to promote activation of an alternate promoter located
within the first intron of theMMP-2 gene, rendering an intra-
cellularly active N-terminal truncated MMP-2 isoform that
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lacks the secretory sequence and the inhibitory prodomain
region [65]. Intracellular activity of MMPs may be further
facilitated by alternative splicing that renders MMP proteins
lacking the secretory signal peptide [2, 3, 66, 67]. Finally,
it has been proposed that intracellular activation of MMPs
can be achieved by proteins belonging to the SIBLING (small
integrin-binding ligand N-linked glycoprotein) family. BSP
(bone sialoprotein), OSP (osteopontin), and DSP1 (dentin
matrix protein 1), all upregulated in different types of cancer,
may, respectively, bind and activate MMP-2, MMP-9, and
MMP-3 without removing the prodomain, but by inducing
conformational changes in the protease [68].
3.2. MMP Activity Correlates with Altered Connexin Expres-
sion. Evidence for the proteolytic processing of Cx proteins
byMMPs ismostly derived from the heart where Cx40, Cx43,
and Cx45 are expressed in a site-specific manner with Cx43
present in atrial tissue and beingmost prevalent in the ventri-
cles. Cx40 and Cx45 are present in SA and AV nodes and in
atrial and ventricular tissue, respectively [69, 70]. In the heart,
GJsmediate electrical coupling and direct cell-to-cell transfer
of chemical and metabolic signals. Consequently, changes of
GJ properties are collectively known to contribute tomyocar-
dial infarction injury and arrhythmogenesis. Intravenous
injection of the proinflammatory cytokine TNF𝛼 increased
MMP-2 levels in mouse atrial tissue which was correlated
with a decrease in Cx40 expression [71]. In canine ventricular
tissue, Cx43 expression became progressively weaker and
disordered with the duration of ventricular fibrillation. At the
same time, a decline in TIMP-2 levels and increase in MMP-
2/TIMP-2 ratio were observed [72]. Cardiac pressure over-
load in TIMP-2 knockout mice was associated with increased
levels of MMP-9 and MMP-14, leading to a decreased
expression of the endocardial Cx37 as well as Cx43, thereby
exacerbating cardiac dysfunction [73]. In cardiac fibroblasts,
expression of both MMP-2 and MMP-9 was increased and
associated with a concomitant decrease in Cx43 expression
after activation of endothelin receptors [74]. Finally, ele-
vated levels of homocysteine, a sulfur-containing nonprotein
amino acid and a strong inducer of oxidative stress, activated
MMP-9 in mouse ventricular myocytes which led to Cx43
mitochondrial translocation and degradation [75]. A link
between Cx expression and MMP activation has also been
described in extracardiac tissues, for example, in the retinal
endothelial cells, where hyperglycemia increased mitochon-
drial MMP-2 activity, leading to a downregulation of Cx43
as well as the induction of apoptotic cell death. Treatment
with MMP-2 small interfering RNAs prevented the decrease
in Cx43 and protected against apoptosis [76]. Oppositely, in
hyperglycemic kidneys, ROS activated MMP-9 which was
accompanied by an upregulation of Cx40 and Cx43 [77].
Despite correlation between increased MMP expression
and decreased Cx expression levels, none of the papers
referred to above unequivocally demonstrated a direct role of
MMP proteolytic activity in regulating Cx expression. In fact,
very few papers have provided such direct evidence. Wu et
al. have recently indicated that, in rat H9C2 cardiomyocytes,
hypoxia decreased the total Cx43 protein level by ∼30–50%
in a MEK/ERK MAPK-dependent and MMP-9-dependent
manner. The Zn2+ chelating compound doxycycline largely
prevented the decline in Cx43 [78]. Doxycycline is best
known as a broad-spectrum antibiotic tetracycline but also
acts as a broad-spectrumMMP inhibitor at subantimicrobial
doses. Furthermore, the most straightforward evidence for
the proteolytic processing of Cx43 by MMPs was provided
by Lindsey et al. [7]. In postmyocardial infarction heart
sections, Cx43 staining was decreased while cardiomyocyte
MMP-7 levelswere significantly increased.Accordingly, Cx43
downregulation was not observed in MMP-7 knockout
mice. Further evaluation by surface plasmon resonance
(SPR) protein binding studies demonstrated a direct and
specific interaction between Cx43 and MMP-7. Importantly,
decreased Cx43 detection levels were observed when using
an antibody targeting the last 10 C-terminal amino acids
(373–382), but not when using an antibody targeting amino
acids (252–270) that are located more upstream in the C-
terminal domain. This argued in favor for the proteolytic
cleavage of Cx43 C-terminal amino acids, rather than an
overall decrease in Cx43 expression levels. In silico analysis
indeed revealed two sites with sequence homology to known
MMP-7 cleavage sequences within the Cx43 C-terminal
domain: 341NQNAKKVAAGHELQPLAIVD360 shows sim-
ilarity with the MMP-7 cleavage sequence GPQAIAGQ;
375PRPDDLEI382 shows similarity with the MMP-7 cleavage
sequence PPEELKFQ [7] (Figure 1).
We performed further in silico analysis of possible MMP
cleavage sites in the human Cx43 C-terminal domain using
PROSPER (http://lightning.med.monash.edu.au/PROSPER/)
[79] and SitePrediction (http://www.dmbr.ugent.be/prx/bi-
oit2-public/SitePrediction/) [80]. SitePrediction uses known
datasets available in literature to identify possible cleavage
sites in a given amino acid sequence. It combines similarity
scores of the candidate sequence with known cleavage sites,
with frequency scores that indicate whether amino acids of
the candidate sequence are likely to occur at the cleavage
domain recognized by a specific protease [80]. SitePrediction
allows predicting of cleavage sites of numerous proteases,
including MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, MMP-12, and MMP-13. Of these, only MMP-2,
MMP-7, and MMP-9 have been described in the context of
altered Cx43 expression/function and we therefore chose to
focus only on these three MMPs. SitePrediction identifies
numerous potential cleavage sites in the Cx43 C-terminal
domain that have 95% specificity (the chance that the
identified site is an actual cleavage site) (Table 1). Analysis
using PROSPER seems more stringent as compared to
SitePrediction as only one cleavage domain is identified for
MMP-2 and no candidate sites for MMP-7 are recognized
(Table 2). Like SitePrediction, PROSPER identifies protease
substrates and their cleavage sites, using info available in
the peptidase database MEROPS. It furthermore combines a
number of complementary sequence and structural features,
including local amino acid sequence profile, predicted
secondary structure, solvent accessibility, and natively
disordered region, as well as some global sequence features,
for predicting cleavage sites of protease substrates [79]. The
resulting probability score (that describes the quantitative
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Figure 1: Predicted MMP cleavage sites of the Cx43 C-terminal domain. In silico analysis using PROSPER and SitePrediction reveals several
potential cleavage sites of MMP-2 (green circles), MMP-7 (pink letters), and MMP-9 (blue circles) in the human Cx43 C-terminal domain.
MMP target domains are 8 amino acids in length (P4-P3-P2-P1-P1󸀠-P2󸀠-P3󸀠-P4󸀠) with the actual MMP cleavage site (between P1 and P1󸀠)
indicated by the arrowhead. In addition, we include one MMP-7 target site published in [7] that is not predicted by in silico analysis using
PROSPER or SitePredict (indicated by the asterisk). Inset depicts the full length topology of Cx43.
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Table 1: Results of cleavage site prediction based on SitePredic-
tion∗ in silico analysis.
Matrix-
metalloprotease Position Segment
Average
score Specificity
MMP-2
357# QPLA −/− IVDQ 476.396 >99%
355 ELQP −/− LAIV 117.022 >99%
277 PTAP −/− LSPM 155.854 >99%
254 TSGA −/− LSPA 106.264 >99%
256 ALSP −/− AKDC 26.467 >95%
326 AGST −/− ISNS 25.335 >95%
252 ATSG −/− ALSP 22.937 >95%
280 PLSP −/−MSPP 19.688 >95%
379 RPDD −/− LEI 18.873 >95%
MMP-7
355 ELQP −/− LAIV 29.767 >99%
287 PGYK −/− LVTG 29.767 >99%
352 AGHE −/− LQPL 5.998 >95%
255 GALS −/− PAKD 5.152 >95%
277 PTAP −/− LSPM 4.057 >95%
379 RPDD −/− LEI 3.397 >95%
253 TSGA −/− LSPS 3.242 >95%
285 SPPG −/− YKLV 2.469 >95%
349 KLAA −/− GHEL 2.431 >95%
238 GVKD −/− RVKG 2.119 >95%
MMP-9
285# SPPG −/− YKLV 47.023 >99%
324 GQAG −/− STIS 35.498 >99%
255 GALS −/− PAKD 13.580 >95%
357# QPLA −/− IVDQ 11.443 >95%
252 ATSG −/− ALSP 11.129 >95%
235 FFKG −/− VKDR 4.991 >95%
∗http://www.dmbr.ugent.be/prx/bioit2-public/SitePrediction/; #also identi-
fied by PROSPER.
Table 2: Results of cleavage site prediction based on PROSPER∗ in
silico analysis.
Matrix-
metalloprotease Position Segment
Probability
score
MMP-2 357# QPLA −/− IVDQ 1.06
MMP-9
357# QPLA −/− IVDQ 1.21
285# SPPG −/− YKLV 1.10
248 DPYH −/− ATTG 1.08
231 LFYV −/− FFKG 1.08
359 LAIV −/− DQRP 1.03
287 PGYK −/− LVTG 1.01
334 HAQP −/− FDFP 0.98
277 PTAP −/− LSPM 0.97
379 RPDD −/− LEI 0.96
∗https://prosper.erc.monash.edu.au; #also identified by SitePrediction.
cleavage probability for each cleavage site) contains a
confidence in the prediction and only cleavage sites with
a predicted cleavage probability score greater than 0.8 are
listed. Only MMP-2, MMP-7, MMP-9, and MMP-3 are
available in PROSPER [79] and we again focused onMMP-2,
MMP-7, and MMP-9 for identifying potential cleavage sites
in the Cx43 protein. Figure 1 summarizes the potential target
sites of MMP-2, MMP-7, andMMP-9 in the Cx43 C-terminal
domain as identified by PROSPER and SitePrediction.
We stress, however, that in silico analysis is predictive and
requires further experimental validation. For instance,
although an interaction between Cx43 and MMP-7 has been
confirmed by SPR [7], PROSPER did not identify MMP-7
as a protease that cleaves Cx43. SitePrediction does, but the
identified domains do not correspond with those described
by Lindsey et al. [7]. In addition, one of the sites identified in
[7] (Figure 1, indicated by ∗) has an average score of 0.005
and a specificity far below 95% in SitePrediction. Oppositely,
both PROSPER and SitePrediction identified MMP-2 as a
potential candidate, but MMP-2 failed to bind Cx43 in SPR
studies [7].
Based on the data presented by Lindsey et al. [7] and
those obtained with in silico analysis demonstrating cleavage
of the C-terminal domain, a careful reevaluation of previous
studies reporting Cx43 downregulation should perhaps be
considered. Indeed, most commercially available antibodies
against Cx43 target the C-terminal domain, but unfortu-
nately, epitopes are not always mentioned in studies claiming
Cx43 downregulation.
3.3. Functional Consequences of C-Terminal Cx43 MMP-
Cleavage at the Channel Level. Cx43 is by far best charac-
terized in terms of the role of its C-terminal domain in
modulating channel function.This domain comprises amino
acids 232–382 and is the primary interaction domain of Cx-
associated partner proteins like ZO-1, tubulin, microtubules,
and caveolins that may regulate protein trafficking and
function [81–83]. Additionally, it is the prime target for
posttranslational modifications such as S-nitrosylation [84]
and phosphorylation [85]. Under both basal and stimulated
conditions, Cx channel activity appears to be regulated by
ongoing phosphorylation-dephosphorylation events. How-
ever, much of the details on how Cx phosphorylation can
determine the activity state of HCs and GJs still remains to
be resolved [85]. Interestingly, certain kinases, including pH-
dependent kinases [86], act on the Cx43 C-terminal domain,
a molecular hotspot for the control of GJ and HC activity.
Phosphorylation of the CT tail may add negative charges
at this site, potentiating an interaction between the CT and
the second half of the cytoplasmic loop (CL), termed the
L2 region (AAs 119–144). As such, the L2 region, which
contains a stretch of positively charged AAs, serves as a
receptor domain for the CT [87, 88]. This intramolecular
CT-CL interaction has been proposed to act as a ball-and-
chain mechanism mediating the closure of GJ channels, for
instance, during voltage gating and chemical gating of GJ
channels by intracellular acidification [89–95] (Figure 2(a)).
The CT-CL interaction is expected to induce a change
in channel conformation that brings the GJs in a closed
state [96]. Strikingly, for Cx43HCs, such CT-CL interaction
is essential for HC opening. This was suggested for the
first time in studies investigating the bimodal response of
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Figure 2: Cx43 channel gating by CT-CL interactions and possible effects of Cx43 C-terminal cleavage on hemichannel function. The
Cx43 C-terminal domain is intricately involved in gating of both HCs and GJ channels. (a) In normal conditions, GJ channels are open,
with the C-terminal domains not interacting with the CLs. GJ closure occurs when the CT binds the CL (ball-and-chain closure). In GJ
channels composed of CT-truncated Cx43, closure via the ball-and-chain mechanism cannot occur and GJ channels remain open. (b) An
intramolecular CT-CL interaction has been proposed to bring Cx43HCs in the “available to open” state whereas in the absence of such
interaction, HCs remain closed. HC closure at above 500 nM [Ca2+]i is mediated by cytoskeletal contractions that dislocate the C-terminal
domain from theCL and act as a brake onHCopening. SuchCT-CL interaction cannot take place inHCs consisting of C-terminally truncated
Cx43, making them refractive for activation. MMP cleavage of Cx43HCs in the “available to open” state will result in a C-terminal peptide
that is bound to the CL. This will cause loss of the high [Ca2+]i brake when the cleavage site is located downstream of the Cx43-actomyosin
interaction site. When theMMP cleavage site is located N-terminally of this actomyosin linker domain, the outcome is less clear. In principle,
actomyosin contractionmay remove theCTpeptide from theCL, but a residual interaction of the CLwithmore upstream sequencesmay keep
the HC in an “available to open” state. Identification of the actomyosin interaction domain within the Cx43 C-terminal domain responsible
for mediating the high [Ca2+]i brake on HC opening will resolve these uncertainties.
Cx43HCs to an increase in [Ca2+]i. A moderate increase in
[Ca2+]i up to 500 nM strongly promotes Cx43HC opening
while this effect disappears with larger [Ca2+]i elevations to
the micromolar level that tend to close the HCs [97–99].
Mechanistically, Ca2+-activation of Cx43HCs is mediated
by calmodulin-dependent signaling [98] and is dependent
on a CT-CL interaction [100] that brings the HCs in the
“available to open” state [96] (Figure 2(b)). Importantly, CT-
CL interaction is a necessary condition for HC opening, but
the actual opening is triggered by membrane depolarization
or moderate (<500 nM) elevation of [Ca2+]i. HC closure at
above 500 nM [Ca2+]i is mediated by cytoskeletal contrac-
tions that pull the C-terminal domain away from the CL
[96, 101] (Figure 2(b)).The latter system acts as a brake onHC
opening and is operational under physiological conditions
presumably to prevent the detrimental effect of uncontrolled
opening of this large conductance channel. The dependence
of Cx43HC opening on a CT-CL interaction stands in stark
contrast to the fact that such interaction results in closure of
GJs [102]. At the molecular level, it is still uncertain why and
how GJs and HCs are differentially modulated by a CT-CL
interaction. Nonjunctional HCs (closed) may adopt different
conformations as compared to those incorporated into GJs
(open). Interactions between subunits during docking of two
HCs may indeed result in conformational changes of the Cx
protein, thereby altering gating properties. Another element
that may contribute is the fact that HCs and GJ channels are
differentially located in different plasma membrane domains
with different properties such as lipid rafts [48].
Like most transmembrane proteins, Cxs are cotransla-
tionally integrated into the rough endoplasmic reticulum
(ER) membrane where they adopt their native transmem-
brane configuration [103, 104]. The subsequent oligomeriza-
tion of Cx proteins into HCs starts in the ER, progressing
to the trans-Golgi network [103, 104]. After leaving the ER-
Golgi intermediate compartment, Cxs then transit through
the cis- and trans-Golgi network before being shuttled to the
PM [56, 105]. Some data indicate that Cx43 is transiently
phosphorylated early in the secretory pathway [106], sug-
gesting that the CT is exposed and available for interaction
with modifying proteins during transit from the ER to the
Golgi network and plasma membrane. Thus, in principle,
intracellular cleavage of theCx43C-terminal domainmaynot
only occur in plasma membrane Cx43 channels, but also in
channels that are “en route” to the plasma membrane. Work
with CT-truncated Cx43 mutants has repetitively shown that
CT-truncated proteins are present at the plasmamembrane of
mammalian cells [93, 107–109]. Consequently, also following
MMP cleavage, channels harboring truncated Cx43 will be
present at the plasma membrane. Note though that in vivo
data describing the trafficking behavior of disease-associated
Cx43 mutations giving rise to preliminary CT-truncated
Cx43 indicates that these truncated proteins are not inserted
in the plasma membrane [110–113].
GJs have generally been shown to remain functionalwhen
composed of truncated Cx43. This has been confirmed by
dye coupling studies for Cx43M239stop [114] and Cx43D378stop
[115] mutants. Dual patch clamp studies have revealed similar
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results at the macroscopic level for Cx43D378stop [115] and
Cx43K258stop. Yet, single channel analysis of the latter revealed
that mean open time was prolonged and transitions to
intermediate, residual open states were lost.This was demon-
strated both in cardiomyocytes [107] and astrocytes [116]. GJs
formed by truncated Cx43 were furthermore found to be
resistant to closure upon intracellular acidosis [117]. Opposite
toGJs, HCs containingCT-truncatedCx43 become refractive
to activation in response to membrane depolarization [34]
and increased [Ca2+]i (Cx43
M239stop [100]) or by omission
of extracellular Ca2+ form the culture medium (Cx43M239stop
[114]), most likely because the CT-CL interaction that is
necessary for HC opening is lost. Opposite results exist
for HCs formed of truncated Cx43 (Cx43M258stop) that still
open in zero Ca2+ conditions [116]. As the mechanism of
Cx43HC opening by depletion of extracellular Ca2+ condi-
tions remains to be fully elucidated, it is uncertain whether
the short, remaining CT stretch in the Cx43M258stop versus the
Cx43M239stop can be responsible for this differential outcome.
C-terminal Cx43 cleavage by MMPs not only results in
a truncated protein with compromised CT-CL interaction
capabilities but also renders small, free endogenous C-
terminal peptides that have potential to alter channel func-
tion in their own right [7]. This is exemplified by application
of exogenous peptides that mimic the last 9 amino acids
of the Cx43 protein (RPRPDDLEI). ACT1, developed by
Gourdie and coworkers, is an example of such a peptide that
is N-terminally linked to an antennapedia cell-penetrating
peptide [118]. ACT1 interferes with the binding of ZO-1 to
the C-terminal domain, thereby sequestering undockedCx43
connexons into GJs, enhancing GJ aggregation and potenti-
ating GJIC, without stimulating Cx43 expression [118, 119].
ACT1 is currently under investigation as a novel therapeutic
in wound healing [120–123] and may also be applicable as
an antiarrhythmogenic compound [124] as well as a tumor
suppressor [125]. The ACT1 peptide was only found effective
as a HC inhibitor in confluent cell monolayers, but not in
semiconfluent cells. It was therefore hypothesized that ACT1
inhibitsHCs only becausemoreHCs are incorporated intoGJ
channels [119]. However, a slightly different picture has been
proposed by Ponsaerts et al. [100]. In this collaborative work,
we used the very same C-terminal peptide (RPRPDDLEI)
but linked to the TAT translocation sequence (derived from
the HIV-1 virus), to investigate HC gating by [Ca2+]i changes
in subconfluent cell cultures. Here, addition of the “TAT-
CT” peptide prevented HC closure at high [Ca2+]i by bind-
ing to the CL, thereby mimicking the endogenous CT-CL
interaction. Exogenously added TAT-CT peptide is thus able
to substitute for the endogenous CT sequence. In line with
this, TAT-CT restored HC activity of C-terminally truncated
Cx43 (Cx43M239stop), while not affecting HC activation by
modest (<500 nM) [Ca2+]i. The lack of TAT-CT effect on
closed Cx43HC in resting conditions points to a scenario
whereby CT-CL interaction is a necessary condition for
HC opening triggered by stimuli such as strong membrane
depolarization or moderate (<500 nM) [Ca2+]i elevation.
Some additional activation steps may be necessary that first
expose the CL domain for subsequent binding of the CT
[96]. In this context, ZO-1 did not seem to play a role in
the modulation of HC function by TAT-CT since a TAT-
CT version lacking the last isoleucine residue, essential for
interaction with ZO-1, was fully capable of alleviating closure
by high [Ca2+]i and of restoring the activity of Cx43
M239stop
HCs [100]. This was later confirmed in Cx43D378stop adult
hearts where Cx43 and ZO-1 still normally colocalized at the
intercalated disk despite the absence of the 5 last C-terminal
amino acids [115]. As a consequence of these considerations,
the peptide resulting from cleavage of the Cx43 C-terminal
domain at 375PRPDDLEI382 as has been described for MMP-
7 [7] and suggested for MMP-9 (Figure 1), may thus prevent
pathological closure of GJs while promoting HC opening
at high [Ca2+]i. On a longer time scale (hours/days), HC
opening may be dampened as suggested by the work with
ACT1 peptide.
Finally, forced expression of Cx43 C-terminal fragments
has additionally revealed their translocation to the nucleus
where they act to inhibit cell growth and abrogate differen-
tiation [126–129]. Thus, MMP generated CT fragments may
potentially act via nuclear signaling as well.
Intriguingly, endogenous, cytoplasmic C-terminal frag-
ments of Cx43, about 20 kDa in size have been observed
in cultured murine and hamster cells and tumor cells and
in cardiac cells subjected to ischemia [130–134]. These nat-
urally occurring fragments have been suggested to result
from internal translation of the GJA1 gene transcript [133]
since their occurrence could not be prevented by the MMP
protease inhibitor EGTA-complete(R) and the serine pro-
tease inhibitor phenylmethylsulfonyl fluoride (PMSF) [131].
However, it looks less convincing that addition of protease
inhibitors in the lysis buffer would prevent the occurrence
of previously MMP-cleaved fragments in the lysate. In
another paper, cleavage was excluded as a possible source
of these fragments because detection with an N-terminal
Cx43 antibody could only reveal full-length protein but not
truncated Cx43 [132]. Obviously, posttranscriptional control
of Cx43 expression at the mRNA level may explain some
of these results but we propose to carefully consider the
alternative option of cleavage by proteases. Indeed, in most
cases, these C-terminal 20 kDa fragments mainly remain at
the observational level and their origin is not discussed.
Particularly in conditions known to induce MMP activity
such as ischemia, protease activity may well contribute to the
cellular production of these fragments.
4. Implications of Altered Connexin Channel
Function in Inflammation
Several studies specifically implicate Cx43HCs in various
injuries and inflammatory pathways. Some evidence comes
from the cardiac system [48, 135, 136] but most evidence
derives from the central nervous system where increased
Cx43 expression has been observed following stroke, epilepsy,
optic nerve damage, spinal cord injury, amyloid plaque
formation, and MS and where Cx43HC opening leads to
increased damage via the inflammatory response [47, 52,
137–144]. Cx43HC opening in inflammatory conditions is
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known to be mediated by advanced glycation end-products
(AGEs) [145], oxidative stress [84, 145], and proinflammatory
cytokines [146, 147]. Almost simultaneously, Retamal et al.
[146] and Morita et al. [147] were the first to show that
exposure of cultured astrocytes to (microglia-derived) proin-
flammatory cytokines such as IL1𝛽 and TNF𝛼 stimulated
Cx43HC opening. This was mediated by the activation of
p38 MAPK and increase in NOS activity and NO production
[146]. Acute opening of astroglial Cx43HCs by IL1𝛼/𝛽 was
later confirmed using live brain slices from mice harboring
S. aureus induced abscesses [148].
Upon opening, Cx43HCs form awell-known pathway for
the release of ATP which is driven by a large concentration
gradient between the intra- and extracellular compartment
[34, 149, 150]. This purinergic messenger is a crucial factor
in establishing a chemotactic signal for infiltrating polymor-
phonuclear neutrophils [151–154]. Modulation of Cx43HCs
and inhibition of ATP release indeed correlate with reduced
tissue invasion of neutrophils [155]. Neutrophils on their part
also release ATP by means of Cx43HCs, further contributing
to the progression of the inflammatory response [156, 157].
In addition, Cx43HC-mediated ATP release can actively
contribute to the activation of the NLRP3 inflammasome, a
protein complex that serves to sense pathogen- and danger-
associated molecular patterns and is involved in IL1𝛽 and
IL18 processing [158]. Using the endothelial cell line b.End5,
Robertson and coworkers have furthermore indicated that
ATP release induces the expression of Toll-like receptor-
2 (TLR2) and production of IL6 upon infection with S.
epidermidis. In turn, TLR2 activation gave rise to a further
upregulation of Cx43 expression, albeit it had no impact
on actual Cx43HC opening [159]. Not only ATP but also
other active compounds released by HCs might contribute
to progression of inflammation. For instance, inhibition
of glutamate release from activated microglia has proven
beneficial in the outcome of spinal cord injury, reducing glial
scar formation and increasing expression of growth factors
[140]. Recently, Cx43HCs were also found to play a role in
neuropathic pain. Here, Cx43 expression was upregulated in
spinal cord astrocytes following chronic constriction injury
and subsequent Cx43HC opening led to the release of the
chemokine CXCL1 [160].
In short, aberrant Cx43HC-mediated signaling may pro-
mote acute inflammation. Intriguingly, all of the above-
mentioned pathological conditions (stroke, epilepsy, bacte-
rial infection, etc.) in which Cx43HCs contribute to inflam-
mation are also associated with increased MMP activity [23,
161–166]. In the following paragraphs we set out a hypothesis
of how proteolytic cleavage of MMPs can contribute to
inflammation.
Interestingly, knockout of theMMPs that have been asso-
ciated with reduced Cx43 expression/function (i.e., MMP-2,
MMP-7, andMMP-9) leads to altered chemotaxis, attenuated
leukocyte influx, and reduced cell death [8, 167–173]. How-
ever, an equal amount of papers describes impaired repair,
increased leukocyte load, and an aggravated inflammatory
response upon knockout of these MMPs [13, 174–176].
As described above, an important feature of the MMPs
is their minor latency of activation, with oxidative stress
and/or expression of proinflammatory cytokines generally
precedingMMPactivity. Interestingly, activation ofCx43HCs
by the proinflammatory cytokines TNF𝛼, IL1𝛽, and IFN𝛾
requires exposure times in the order of 9 h [177], 24 h [146],
and 48 h [178]. These very slow actions may well reflect
the involvement of MMPs. Additionally, MMP expression
and activity depend on an increase of [Ca2+]i triggered
by proinflammatory cytokines [179]. This [Ca2+]i increase
will also activate Cx43HC opening when HCs are in the
“available to open” state. Subsequent MMP-cleavage in the
CTwill generate a C-terminal peptide that is bound to the CL
(Figure 2(b)). The consequent effect of proteolytic cleavage
on HC function may depend on the position of the MMP
cleavage site relative to the yet unidentified Cx43-actomyosin
interaction domain(s) in the Cx43 C-terminal tail that medi-
ates high [Ca2+]i-induced HC closure (“high [Ca
2+
]i brake”).
When cleavage occurs at a site that is situated C-terminally
from the Cx43-actomyosin interaction domain, it is expected
that the C-terminal peptide cannot be removed from the
CL by cytoskeletal/actomyosin contractions (see Section 3.3).
Thus, HCs remain in the “available to open” state (with
effective opening triggered by membrane depolarization or
[Ca2+]i increase), but the high [Ca
2+
]i brake disappears,
thereby promoting HC opening in cells with pathologically
high [Ca2+]i (Figure 2(b)). Alternatively, when cleavage takes
place at a site that lies upstream at the N-terminal side of
the actomyosin linkage domain, the outcome is less clear.
Theoretically, it is possible that cytoskeletal contractions
remove the C-terminal peptide from the CL; however, multi-
ple amino acid domains in the CTmay participate in the CT-
CL interaction. Indeed, Cx43C-terminal amino acid domains
281–295, 299–304, 341–327, 342–348, and 360–382 have all
been shown to engage in the intramolecular interactions
necessary for ball-and-chain GJ channel gating [180, 181]. For
Cx43HCs, at present, only the last 10 amino acids have been
described to contribute to the CT-CL interaction necessary
for promoting HC opening. However, as for GJs, it is to be
expected that more upstream domains also participate in this
intramolecular interaction. Identification of the actomyosin
interaction site in the Cx43 C-terminal domain will allow
us to further define the effects of MMP cleavage upstream
(N-terminally) of the actomyosin linkage domain on HC
function. For GJ channels, various proteins have been sug-
gested to function as a linker between the cytoskeleton and
the Cx43 C-terminal tail, including drebrin [182], cortactin
[183], ezrin [184], Src [185], CIP85 [186], CCN3 [187], and
ZO-1 [100, 188, 189]. For HCs, the latter can be excluded as
the intermediate between the cytoskeleton and the Cx43 C-
terminal domain [100]; however, whether the other candidate
proteins, mentioned in the context of GJs, also interact with
Cx43HCs remains to be confirmed.
Oxidative stress, that is tightly linked to the intracellular
Ca2+ household [190] and to fast, intracellular MMP acti-
vation, has also been shown to promote Cx43HC opening
within a time frame of several minutes [84, 191]. As described
above, MMP cleavage may in this case further promote HC
opening mediated by a loss of their high [Ca2+]i brake.
Interestingly, Cx43HCs themselves may subsequently act as
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an entry channel for ROS that may further activate MMPs
and HC through a positive feedback loop [191].
Increased opening of Cx43HCs following proteolytic
processing by MMPs would give rise to exaggerated ATP
release and leukocyte infiltration, altogether aggravating the
inflammatory response. Additionally, persistent loss of ATP
and nutrients would also result in cellular energy deprivation
and ultimately cell death. Furthermore, in the brain, elevated
levels of glutamate in the cerebral interstitial fluid are known
to be excitotoxic and so HC glutamate release by microglial
cells would give rise to neurodegeneration. Although HC
opening in inflammatory conditions is generally considered
deleterious for the cell, a few reports indicate that HC
opening may act protective, for example, by releasing signal-
ing molecules that activate Src and ERK-mediated survival
signals or by releasing prostaglandin E2 that protects against
apoptosis [192–194].
Opposite to HCs, generally taken, GJIC is reduced in
inflammatory conditions, as shown for proinflammatory
cytokines, ATP, and oxidative stress [146, 195–200]. Such
uncoupling has dual effects on the inflamed tissue; on the one
hand, it may act as a protective mechanism that encapsulates
the injured cells and functionally separates them from the
surrounding healthy tissue. However, at the same time,
uncoupling also impedes the supply of energy and nutrients
that are necessary for tissue repair processes. Notably, con-
trasting reports that describe persisting functional GJIC in
inflammation are available as well [159, 201, 202]. GJs have,
for instance, been shown to propagate oxidative stress and
bystander cell death [32, 203]. Additionally, coupled cells are
able to share antigens with and trigger a response in cytotoxic
T-lymphocytes [204]. Finally, GJs have been suggested to
mediate the propagation of NF𝜅B andMAPK activation from
infected to noninfected cells, leading to IL8 production, also
by the latter [201]. Interestingly, using a brain abscess model,
Karpuk et al. [46] have indicated that the degree of GJIC
inhibition is dependent on the distance to the lesion site and
that coupling gradually increases with expanding distance
from the lesion site. Despite the upregulation of Cx43 expres-
sion, uncoupling was observed at the third day after infection
and persisted up to the 7th day, indicating a long lasting
effect [46]. The mechanisms that mediate such persistent
block ofGJICwithout affecting expression levels are currently
unknown. Given the double role of GJIC, the differential
outcome of uncoupling in inflammation, and uncertainties
regarding the detailed mechanisms of uncoupling, it is very
difficult to speculate on the functional outcome of proteolytic
cleavage mediated by MMPs in terms of GJIC and its impact
on inflammation.
Finally, CT truncation not only should be considered
relevant in view of intramolecular gating mechanisms and
single channel function but is also of utmost importance
at the level of protein-protein interactions. As mentioned
above, the Cx43 C-terminal domain contains interaction
sites for, for example, ZO-1, occludin, claudin, tubulin, and
the protooncogene Src [205, 206]. Deletion of the last 5
amino acids has no functional effects of the level of GJIC
but nevertheless induces arrhythmogenesis due to aberrant,
channel independent interactions of Cx43 with sodium and
potassium channels [115]. The purinergic receptor P2Y1 is
another example protein believed to interact with the C-
terminal domain of Cx43 and its expression is reduced in
Cx43 knockout animals [207, 208]. Via their interaction with
proteins that contribute to tight and adherens junctions (e.g.,
ZO-1 and occludin), Cxs stabilize the junctional complex
that is situated between epithelial and endothelial cells and
impedes paracellular diffusion [209–212]. A reduction in
Cx43 expression is often accompanied by a downregulation of
the junctional proteins leading to compromised intercellular
junctions. Importantly, destabilization of the junctions abro-
gates the barrier function of epithelial and endothelial cells
and therefore facilitates the paracellular movement of leuko-
cytes into the inflamed tissue. On the other hand, exposure
of astrocytes to IL1𝛽 leads to a concomitant downregulation
of Cx43 and upregulation of the tight junctional protein
claudin-1. It is believed that the latter brings astrocytes closer
together, reducing the extracellular space volume and forcing
inflammatory molecules to move in a particular direction
[198]. Notably, connexin protein interactions with junctional
proteins also stabilize the GJ plaques [213, 214]. In addition,
many of the Cx43 interaction partners, including ZO-1 and
occludin, are also MMP substrates and their proteolytic
cleavage is expected to induce GJ uncoupling. Yet, such
matter is ought to be addressed in future studies.
5. Conclusions
Via their remodeling of ECM and intercellular junctions
as well as by their proteolytic processing of cytokines,
chemokines, and growth factors, MMPs importantly con-
tribute to inflammation, a process in which they are known to
have beneficial as well as detrimental functions. In this paper
we specifically describe the regulation of Cx43 expression and
channel function by the intracellular action of MMPs. Cx43
is the most prevalent building block of GJs and HCs, two
types of channels intricately involved in tissue homeostasis
as well as in acute inflammation. A handful of reports
describe a link between altered expression of Cx43 on the
one hand and elevated levels of MMP activation on the
other. In silico analysis additionally demonstrates that MMPs
are capable of mediating cleavage of the Cx43 C-terminal
domain which is an important determinant of HC and
GJ channel function. Such cleavage has also been directly
demonstrated in cardiac tissue where it contributes to tissue
damage followingmyocardial infarction. Unfortunately, until
now, no studies have been performed that unequivocally
demonstrate the direct impact of MMPs on channel function
at the mechanistic level. We here explain the possible effects
of C-terminal cleavage on Cx43 channel function, using
available information that comes from work with Cx43
truncated mutants and studies with exogenous C-terminal
peptides as a basis. However, in inflammatory conditions
where the oligomerized Cx43 protein is cleaved in the plasma
membrane instead of being exogenously expressed as a
truncated mutant, the underlying mechanisms may be very
different. In addition, much like MMPs, the contribution
of GJs and HCs to the inflammatory process seems very
diverse with inhibition of the channels resulting in a positive
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as well as a negative outcome, depending on the tissue, the
trigger, and the timing. Therefore, future challenges will be
to better understand the role of MMPs and Cx43 channels
in inflammation and to gain detailed insight in the nature
of MMP-Cx interactions as well as in the effects on channel
function before gearing up to the therapeutic level.
Conflict of Interests
The authors declare no conflict of interests.
Acknowledgments
This work is supported by the Fund for Scientific Research
Flanders (FWO-Vlaanderen), Belgium (grant nos. G.0298.11,
G.0571.12, G.0A54.13, and G.0320.15), and the Interuniversity
Attraction Poles Program (Belgian Science Policy, Projects
P7/10 and P7/13) granted to Luc Leybaert.
References
[1] V. W. Yong, “Metalloproteinases: mediators of pathology and
regeneration in the CNS,” Nature Reviews Neuroscience, vol. 6,
no. 12, pp. 931–944, 2005.
[2] A. K. Chow, J. Cena, and R. Schulz, “Acute actions and
novel targets of matrix metalloproteinases in the heart and
vasculature,” British Journal of Pharmacology, vol. 152, no. 2, pp.
189–205, 2007.
[3] B. Cauwe and G. Opdenakker, “Intracellular substrate cleavage:
a novel dimension in the biochemistry, biology and pathology
of matrix metalloproteinases,” Critical Reviews in Biochemistry
and Molecular Biology, vol. 45, no. 5, pp. 351–423, 2010.
[4] L. Nissinen and V.-M. Ka¨ha¨ri, “Matrix metalloproteinases in
inflammation,” Biochimica et Biophysica Acta—General Sub-
jects, vol. 1840, no. 8, pp. 2571–2580, 2014.
[5] R. Khokha, A. Murthy, and A. Weiss, “Metalloproteinases and
their natural inhibitors in inflammation and immunity,”Nature
Reviews Immunology, vol. 13, no. 9, pp. 649–665, 2013.
[6] M. Giannandrea and W. C. Parks, “Diverse functions of matrix
metalloproteinases during fibrosis,”Disease Models andMecha-
nisms, vol. 7, no. 2, pp. 193–203, 2014.
[7] M. L. Lindsey, G. P. Escobar, R. Mukherjee et al., “Matrix
metalloproteinase-7 affects connexin-43 levels, electrical con-
duction, and survival after myocardial infarction,” Circulation,
vol. 113, no. 25, pp. 2919–2928, 2006.
[8] P. Van Lint and C. Libert, “Chemokine and cytokine processing
by matrix metalloproteinases and its effect on leukocyte migra-
tion and inflammation,” Journal of Leukocyte Biology, vol. 82,
no. 6, pp. 1375–1381, 2007.
[9] A. Schubert-Unkmeir, C. Konrad, H. Slanina, F. Czapek, S.
Hebling, and M. Frosch, “Neisseria meningitidis induces brain
microvascular endothelial cell detachment from the matrix and
cleavage of occludin: a role for MMP-8,” PLoS Pathogens, vol. 6,
no. 4, Article ID e1000874, 2010.
[10] A. Reijerkerk, G. Kooij, S. M. A. Van Der Pol, S. Khazen, C.
D. Dijkstra, and H. E. De Vries, “Diapedesis of monocytes
is associated with MMP-mediated occludin disappearance in
brain endothelial cells,” The FASEB Journal, vol. 20, no. 14, pp.
2550–2552, 2006.
[11] D.-Y. Lu, W.-H. Yu, W.-L. Yeh et al., “Hypoxia-induced matrix
metalloproteinase-13 expression in astrocytes enhances perme-
ability of brain endothelial cells,” Journal of Cellular Physiology,
vol. 220, no. 1, pp. 163–173, 2009.
[12] D. Navaratna, P. G. McGuire, G. Menicucci, and A. Das, “Pro-
teolytic degradation of VE-cadherin alters the blood-retinal
barrier in diabetes,”Diabetes, vol. 56, no. 9, pp. 2380–2387, 2007.
[13] J. K. McGuire, Q. Li, and W. C. Parks, “Matrilysin (matrix
metalloproteinase-7) mediates E-cadherin ectodomain shed-
ding in injured lung epithelium,” The American Journal of
Pathology, vol. 162, no. 6, pp. 1831–1843, 2003.
[14] Y. Ichikawa, T. Ishikawa, N. Momiyama et al., “Matrilysin
(MMP-7) degrades VE-cadherin and accelerates accumulation
of beta-catenin in the nucleus of humanumbilical vein endothe-
lial cells,” Oncology Reports, vol. 15, no. 2, pp. 311–315, 2006.
[15] G. A. McQuibban, J.-H. Gong, E. M. Tam, C. A. G. McCulloch,
I. Clark-Lewis, and C.M. Overall, “Inflammation dampened by
gelatinase a cleavage of monocyte chemoattractant protein-3,”
Science, vol. 289, no. 5482, pp. 1202–1206, 2000.
[16] A. Ito, A. Mukaiyama, Y. Itoh et al., “Degradation of interleukin
1beta by matrix metalloproteinases,” The Journal of Biological
Chemistry, vol. 271, no. 25, pp. 14657–14660, 1996.
[17] Y.-P. Han, T.-L. Tuan, M. Hughes, H. Wu, and W. L. Garner,
“Transforming growth factor-𝛽- and tumor necrosis factor-𝛼
-mediated induction and proteolytic activation of MMP-9 in
human skin,” Journal of Biological Chemistry, vol. 276, no. 25,
pp. 22341–22350, 2001.
[18] T. Sakai, F. Kambe, H. Mitsuyama et al., “Tumor necrosis factor
𝛼 induces expression of genes for matrix degradation in human
chondrocyte-like HCS-2/8 cells through activation of NF-𝜅B:
abrogation of the tumor necrosis factor 𝛼 effect by proteasome
inhibitors,” Journal of Bone and Mineral Research, vol. 16, no. 7,
pp. 1272–1280, 2001.
[19] M. P. Vincenti, C. I. Coon, and C. E. Brinckerhoff, “Nuclear
factor 𝜅B/p50 activates an element in the distal matrix metal-
loproteinase 1 promoter in interleukin-1𝛽-stimulated synovial
fibroblasts,” Arthritis & Rheumatism, vol. 41, no. 11, pp. 1987–
1994, 1998.
[20] F. Mannello, F. Luchetti, E. Falcieri, and S. Papa, “Multiple roles
of matrix metalloproteinases during apoptosis,” Apoptosis, vol.
10, no. 1, pp. 19–24, 2005.
[21] R. E. Vandenbroucke and C. Libert, “Is there new hope for ther-
apeutic matrix metalloproteinase inhibition?” Nature Reviews
Drug Discovery, 2014.
[22] N. T. V. Le, M. Xue, L. A. Castelnoble, and C. J. Jackson, “The
dual personalities of matrix metalloproteinases in inflamma-
tion,” Frontiers in Bioscience, vol. 12, no. 4, pp. 1475–1487, 2007.
[23] G. A. Rosenberg, “Matrix metalloproteinases in neuroinflam-
mation,” Glia, vol. 39, no. 3, pp. 279–291, 2002.
[24] D. B. Alexander and G. S. Goldberg, “Transfer of biologically
important molecules between cells through gap junction chan-
nels,” Current Medicinal Chemistry, vol. 10, no. 19, pp. 2045–
2058, 2003.
[25] J. Neuhaus, A. Weimann, J.-U. Stolzenburg, H. Wolburg, L.-C.
Horn, and W. Dorschner, “Smooth muscle cells from human
urinary bladder express connexin 43 in vivo and in vitro,”World
journal of urology, vol. 20, no. 4, pp. 250–254, 2002.
[26] H. Miyoshi, M. B. Boyle, L. B. MacKay, and R. E. Garfield,
“Voltage-clamp studies of gap junctions between uterinemuscle
cells during term and preterm labor,”Biophysical Journal, vol. 71,
no. 3, pp. 1324–1334, 1996.
12 Mediators of Inflammation
[27] L. Leybaert and M. J. Sanderson, “Intercellular Ca2+ waves:
mechanisms and function,” Physiological Reviews, vol. 92, no.
3, pp. 1359–1392, 2012.
[28] N. Rouach, A. Koulakoff, V. Abudara, K. Willecke, and C.
Giaume, “Astroglial metabolic networks sustain hippocampal
synaptic transmission,” Science, vol. 322, no. 5907, pp. 1551–1555,
2008.
[29] C. Giaume, A. Tabernero, and J. M. Medina, “Metabolic traf-
ficking through astrocytic gap junctions,” Glia, vol. 21, no. 1, pp.
114–123, 1997.
[30] M.Maes, E. Decrock, B. Cogliati et al., “Connexin and pannexin
(hemi)channels in the liver,” Frontiers in Physiology, vol. 4,
article 405, 2014.
[31] N. Batra, R. Kar, and J. X. Jiang, “Gap junctions and hemichan-
nels in signal transmission, function and development of bone,”
Biochimica et Biophysica Acta: Biomembranes, vol. 1818, no. 8,
pp. 1909–1918, 2012.
[32] E. Decrock, D. V. Krysko, M. Vinken et al., “Transfer of IP
3
through gap junctions is critical, but not sufficient, for the
spread of apoptosis,” Cell Death and Differentiation, vol. 19, no.
6, pp. 947–957, 2012.
[33] D. L. Paul, L. Ebihara, L. J. Takemoto, K. I. Swenson, and D. A.
Goodenough, “Connexin46, a novel lens gap junction protein,
induces voltage-gated currents in nonjunctional plasma mem-
brane of Xenopus oocytes,”The Journal of Cell Biology, vol. 115,
no. 4, pp. 1077–1089, 1991.
[34] J. Kang, N. Kang, D. Lovatt et al., “Connexin 43 hemichannels
are permeable to ATP,”The Journal of Neuroscience, vol. 28, no.
18, pp. 4702–4711, 2008.
[35] Z.-C. Ye, M. S. Wyeth, S. Baltan-Tekkok, and B. R. Ransom,
“Functional hemichannels in astrocytes: a novel mechanism of
glutamate release,” Journal of Neuroscience, vol. 23, no. 9, pp.
3588–3596, 2003.
[36] S. Rana and R. Dringen, “Gap junction hemichannel-mediated
release of glutathione from cultured rat astrocytes,” Neuro-
science Letters, vol. 415, no. 1, pp. 45–48, 2007.
[37] D. A. Goodenough and D. L. Paul, “Beyond the gap: functions
of unpaired connexon channels,”Nature ReviewsMolecular Cell
Biology, vol. 4, no. 4, pp. 285–294, 2003.
[38] J. X. Jiang andP. P. Cherian, “Hemichannels formed by connexin
43 play an important role in the release of prostaglandin
E(2) by osteocytes in response to mechanical strain,” Cell
Communication and Adhesion, vol. 10, pp. 259–264, 2003.
[39] J. A. Orellana, X. F. Figueroa, H. A. Sa´nchez, S. Contreras-
Duarte, V. Velarde, and J. C. Sa´ez, “Hemichannels in the neu-
rovascular unit and white matter under normal and inflamed
conditions,”CNSandNeurologicalDisorders—DrugTargets, vol.
10, no. 3, pp. 404–414, 2011.
[40] C. D’hondt, J. Iyyathurai, B. Himpens, L. Leybaert, and G.
Bultynck, “Cx43-hemichannel function and regulation in phys-
iology and pathophysiology: insights from the bovine corneal
endothelial cell system and beyond,” Frontiers in Physiology, vol.
5, article 348, 2014.
[41] M. Kamermans, I. Fahrenfort, K. Schultz, U. Janssen-Bienhold,
T. Sjoerdsma, and R. Weiler, “Hemichannel-mediated inhibi-
tion in the outer retina,” Science, vol. 292, no. 5519, pp. 1178–1180,
2001.
[42] R. Civitelli, “Cell-cell communication in the osteoblast/osteo-
cyte lineage,” Archives of Biochemistry and Biophysics, vol. 473,
no. 2, pp. 188–192, 2008.
[43] M. De Bock, M. Culot, N.Wang et al., “Connexin channels pro-
vide a target to manipulate brain endothelial calcium dynamics
and blood-brain barrier permeability,” Journal of Cerebral Blood
Flow and Metabolism, vol. 31, no. 9, pp. 1942–1957, 2011.
[44] R. T. R. Huckstepp, R. IdBihi, R. Eason et al., “Connexin
hemichannel-mediated CO
2
-dependent release of ATP in the
medulla oblongata contributes to central respiratory chemosen-
sitivity,” The Journal of Physiology, vol. 588, no. 20, pp. 3901–
3920, 2010.
[45] C. W. Wong, T. Christen, I. Roth et al., “Connexin37 pro-
tects against atherosclerosis by regulating monocyte adhesion,”
Nature Medicine, vol. 12, no. 8, pp. 950–954, 2006.
[46] N. Karpuk, M. Burkovetskaya, T. Fritz, A. Angle, and T. Kielian,
“Neuroinflammation leads to region-dependent alterations in
astrocyte gap junction communication and hemichannel activ-
ity,” Journal of Neuroscience, vol. 31, no. 2, pp. 414–425, 2011.
[47] S. J. O’Carroll, M. Alkadhi, L. F. B. Nicholson, and C. R. Green,
“Connexin43 mimetic peptides reduce swelling, astrogliosis,
and neuronal cell death after spinal cord injury,” Cell Commu-
nication and Adhesion, vol. 15, no. 1-2, pp. 27–42, 2008.
[48] N. Wang, E. de Vuyst, R. Ponsaerts et al., “Selective inhibition
of Cx43 hemichannels by Gap19 and its impact on myocardial
ischemia/reperfusion injury,” Basic Research in Cardiology, vol.
108, no. 1, article 309, 2013.
[49] X. Wang, A. Ma, W. Zhu et al., “The role of connexin 43 and
hemichannels correlated with the astrocytic death following
ischemia/reperfusion insult,” Cellular andMolecular Neurobiol-
ogy, vol. 33, no. 3, pp. 401–410, 2013.
[50] H. V. Danesh-Meyer, N. M. Kerr, J. Zhang et al., “Connexin43
mimetic peptide reduces vascular leak and retinal ganglion cell
death following retinal ischaemia,” Brain, vol. 135, no. 2, pp.
506–520, 2012.
[51] H. V. Danesh-Meyer, R. Huang, L. F. B. Nicholson, and C. R.
Green, “Connexin43 antisense oligodeoxynucleotide treatment
down-regulates the inflammatory response in an in vitro
interphase organotypic culturemodel of optic nerve ischaemia,”
Journal of Clinical Neuroscience, vol. 15, no. 11, pp. 1253–1263,
2008.
[52] J. O. Davidson, C. R. Green, L. F. B. Nicholson et al., “Connexin
hemichannel blockade improves outcomes in a model of fetal
ischemia,” Annals of Neurology, vol. 71, no. 1, pp. 121–132, 2012.
[53] J. E. Contreras, H. A. Sa´nchez, L. P. Ve´liz, F. F. Bukauskas, M. V.
L. Bennett, and J. C. Sa´ez, “Role of connexin-based gap junction
channels and hemichannels in ischemia-induced cell death in
nervous tissue,”Brain Research Reviews, vol. 47, no. 1–3, pp. 290–
303, 2004.
[54] P. Bargiotas, H. Monyer, and M. Schwaninger, “Hemichannels
in cerebral ischemia,” Current Molecular Medicine, vol. 9, no. 2,
pp. 186–194, 2009.
[55] E. Decrock, E. De Vuyst, M. Vinken et al., “Connexin 43
hemichannels contribute to the propagation of apoptotic cell
death in a rat C6 glioma cell model,” Cell Death and Differen-
tiation, vol. 16, no. 1, pp. 151–163, 2009.
[56] D. W. Laird, “Life cycle of connexins in health and disease,”
Biochemical Journal, vol. 394, no. 3, pp. 527–543, 2006.
[57] D.H. Choi, E.-M. Kim,H. J. Son et al., “A novel intracellular role
of matrix metalloproteinase-3 during apoptosis of dopaminer-
gic cells,” Journal of Neurochemistry, vol. 106, no. 1, pp. 405–415,
2008.
[58] B. Cauwe, E. Martens, P. Proost, and G. Opdenakker, “Mul-
tidimensional degradomics identifies systemic autoantigens
Mediators of Inflammation 13
and intracellular matrix proteins as novel gelatinase B/MMP-9
substrates,” Integrative Biology, vol. 1, no. 5-6, pp. 404–426, 2009.
[59] E. Hadler-Olsen, A. I. Solli, A. Hafstad, J.-O. Winberg, and L.
Uhlin-Hansen, “IntracellularMMP-2 activity in skeletal muscle
is associated with type II fibers,” Journal of Cellular Physiology,
vol. 230, no. 1, pp. 160–169, 2015.
[60] G. Soslau, C. Mason, S. Lynch et al., “Intracellular matrix
metalloproteinase-2 (MMP-2) regulates human platelet activa-
tion via hydrolysis of talin,” Thrombosis and Haemostasis, vol.
111, no. 1, pp. 140–153, 2013.
[61] G. Sawicki, E. J. Sanders, E. Salas, M. Wozniak, J. Rodrigo,
andM.W. Radomski, “Localization and translocation of MMP-
2 during aggregation of human platelets,” Thrombosis and
Haemostasis, vol. 80, no. 5, pp. 836–839, 1998.
[62] S.-T. Vilen, P. Nyberg, M. Hukkanen et al., “Intracellular co-
localization of trypsin-2 andmatrixmetalloprotease-9: possible
proteolytic cascade of trypsin-2, MMP-9 and enterokinase in
carcinoma,” Experimental Cell Research, vol. 314, no. 4, pp. 914–
926, 2008.
[63] G. Sawicki, “Intracellular regulation of matrix metalloprotein-
ase-2 activity: new strategies in treatment and protection of
heart subjected to oxidative stress,” Scientifica, vol. 2013, Article
ID 130451, 12 pages, 2013.
[64] E. R. Frears, Z. Zhang, D. R. Blake, J. P. O’Connell, and P. G.
Winyard, “Inactivation of tissue inhibitor of metalloproteinase-
1 by peroxynitrite,” FEBS Letters, vol. 381, no. 1-2, pp. 21–24, 1996.
[65] D. H. Lovett, R. Mahimkar, R. L. Raffai et al., “N-terminal
truncated intracellular matrix metalloproteinase-2 induces car-
diomyocyte hypertrophy, inflammation and systolic heart fail-
ure,” PLoS ONE, vol. 8, no. 7, Article ID e68154, 2013.
[66] M. A.M. Ali, A. K. Chow, A. D. Kandasamy et al., “Mechanisms
of cytosolic targeting of matrix metalloproteinase-2,” Journal of
Cellular Physiology, vol. 227, no. 10, pp. 3397–3404, 2012.
[67] D. Luo, B.Mari, I. Stoll, and P. Anglard, “Alternative splicing and
promoter usage generates an intracellular stromelysin 3 isoform
directly translated as an active matrix metalloproteinase,” The
Journal of Biological Chemistry, vol. 277, no. 28, pp. 25527–25536,
2002.
[68] N. S. Fedarko, A. Jain, A. Karadag, and L. W. Fisher, “Three
small integrin binding ligand N-linked glycoproteins (SIB-
LINGs) bind and activate specific matrix metalloproteinases,”
The FASEB Journal, vol. 18, no. 6, pp. 734–736, 2004.
[69] S. Giovannone, B. F. Remo, and G. I. Fishman, “Channeling
diversity: gap junction expression in the heart,” Heart Rhythm,
vol. 9, no. 7, pp. 1159–1162, 2012.
[70] S. Verheule and S. Kaese, “Connexin diversity in the heart:
insights from transgenic mouse models,” Frontiers in Pharma-
cology, vol. 4, article 81, 2013.
[71] R. Liew, K. Khairunnisa, Y. Gu et al., “Role of tumor necrosis
factor-alpha in the pathogenesis of atrial fibrosis and develop-
ment of an arrhythmogenic substrate,” Circulation Journal, vol.
77, no. 5, pp. 1171–1179, 2013.
[72] J. Wang, J.-S. Li, H.-Z. Liu et al., “Dynamic alterations of
connexin43, matrix metalloproteinase-2 and tissue inhibitor
of matrix metalloproteinase-2 during ventricular fibrillation in
canine,” Molecular and Cellular Biochemistry, vol. 391, no. 1-2,
pp. 259–266, 2014.
[73] S. Givvimani, S. Kundu, N. Narayanan et al., “TIMP-2 mutant
decreases MMP-2 activity and augments pressure overload
induced LV dysfunction and heart failure,” Archives of Physiol-
ogy and Biochemistry, vol. 119, no. 2, pp. 65–74, 2013.
[74] H.-J. Peng, D.-Z. Dai, H. Ji, and Y. Dai, “The separate roles
of endothelin receptors participate in remodeling of matrix
metalloproteinase and connexin 43 of cardiac fibroblasts in
maladaptive response to isoproterenol,” European Journal of
Pharmacology, vol. 634, no. 1–3, pp. 101–106, 2010.
[75] N. Tyagi, J. C. Vacek, S. Givvimani, U. Sen, and S. C. Tyagi,
“Cardiac specific deletion of N-methyl-d-aspartate receptor
1 ameliorates mtMMP-9 mediated autophagy/mitophagy in
hyperhomocysteinemia,” Journal of Receptors and Signal Trans-
duction, vol. 30, no. 2, pp. 78–87, 2010.
[76] G. Mohammad and R. A. Kowluru, “Novel role of mitochon-
drial matrixmetalloproteinase-2 in the development of diabetic
retinopathy,” Investigative Ophthalmology and Visual Science,
vol. 52, no. 6, pp. 3832–3841, 2011.
[77] S. Kundu, S. B. Pushpakumar, A. Tyagi, D. Coley, and U. Sen,
“Hydrogen sulfide deficiency and diabetic renal remodeling:
role of matrix metalloproteinase-9,” The American Journal of
Physiology—Endocrinology andMetabolism, vol. 304, no. 12, pp.
E1365–E1378, 2013.
[78] X. Wu, W. Huang, G. Luo, and L. A. Alain, “Hypoxia induces
connexin 43 dysregulation by modulating matrix metallopro-
teinases via MAPK signaling,”Molecular and Cellular Biochem-
istry, vol. 384, no. 1-2, pp. 155–162, 2013.
[79] J. Song, H. Tan, A. J. Perry et al., “PROSPER: an integrated
feature-based tool for predicting protease substrate cleavage
sites,” PLoS ONE, vol. 7, no. 11, Article ID e50300, 2012.
[80] J. Verspurten, K. Gevaert, W. Declercq, and P. Vandenabeele,
“SitePredicting the cleavage of proteinase substrates,” Trends in
Biochemical Sciences, vol. 34, no. 7, pp. 319–323, 2009.
[81] B. N. G. Giepmans, I. Verlaan, and W. H. Moolenaar,
“Connexin-43 interactions with ZO-1 and alpha- and beta-
tubulin,” Cell Communication and Adhesion, vol. 8, no. 4–6, pp.
219–223, 2001.
[82] S. Langlois, K. N. Cowan, Q. Shao, B. J. Cowan, and D. W.
Laird, “Caveolin-1 and -2 interact with connexin43 and regulate
gap junctional intercellular communication in keratinocytes,”
Molecular Biology of the Cell, vol. 19, no. 3, pp. 912–928, 2008.
[83] A. Saidi Brikci-Nigassa, M.-J. Clement, T. Ha-Duong et al.,
“Phosphorylation controls the interaction of the connexin43 C-
terminal domain with tubulin and microtubules,” Biochemistry,
vol. 51, no. 21, pp. 4331–4342, 2012.
[84] M. A. Retamal, C. J. Corte´s, L. Reuss, M. V. L. Bennett, and
J. C. Sa´ez, “S-nitrosylation and permeation through connexin
43 hemichannels in astrocytes: induction by oxidant stress
and reversal by reducing agents,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103, no.
12, pp. 4475–4480, 2006.
[85] S. R. Johnstone, M. Billaud, A. W. Lohman, E. P. Taddeo, and B.
E. Isakson, “Posttranslational modifications in connexins and
pannexins,” Journal of Membrane Biology, vol. 245, no. 5-6, pp.
319–332, 2012.
[86] P. Yahuaca, J. F. Ek-Vitorin, P. Rush,M. Delmar, and S.M. Taffet,
“Identification of a protein kinase activity that phosphorylates
connexin43 in a pH-dependent manner,” Brazilian Journal of
Medical and Biological Research, vol. 33, no. 4, pp. 399–406,
2000.
[87] H. S. Duffy, P. L. Sorgen, M. E. Girvin et al., “pH-dependent
intramolecular binding and structure involving Cx43 cytoplas-
mic domains,”The Journal of Biological Chemistry, vol. 277, no.
39, pp. 36706–36714, 2002.
[88] A. Seki, H. S. Duffy, W. Coombs, D. C. Spray, S. M. Taffet,
and M. Delmar, “Modifications in the biophysical properties
14 Mediators of Inflammation
of connexin43 channels by a peptide of the cytoplasmic loop
region,” Circulation Research, vol. 95, no. 4, pp. e22–e28, 2004.
[89] M. Delmar, W. Coombs, P. Sorgen, H. S. Duffy, and S. M. Taffet,
“Structural bases for the chemical regulation of Connexin43
channels,” Cardiovascular Research, vol. 62, no. 2, pp. 268–275,
2004.
[90] J. F. Ek-Vitor´ın, G. Calero, G. E. Morley, W. Coombs, S. M.
Taffet, andM.Delmar, “pH regulation of connexin43:molecular
analysis of the gating particle,” Biophysical Journal, vol. 71, no. 3,
pp. 1273–1284, 1996.
[91] F. F. Bukauskas, K. Jordan, A. Bukauskiene et al., “Clustering of
connexin 43-enhanced green fluorescent protein gap junction
channels and functional coupling in living cells,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 97, no. 6, pp. 2556–2561, 2000.
[92] J. M. B. Anumonwo, S. M. Taffet, H. Gu, M. Chanson, A.
P. Moreno, and M. Delmar, “The carboxyl terminal domain
regulates the unitary conductance and voltage dependence of
connexin40 gap junction channels,” Circulation Research, vol.
88, no. 7, pp. 666–673, 2001.
[93] A. P. Moreno, M. Chanson, J. Anumonwo et al., “Role of the
carboxyl terminal of connexin43 in transjunctional fast voltage
gating,” Circulation Research, vol. 90, no. 4, pp. 450–457, 2002.
[94] J. Shibayama, C. Gutie´rrez, D. Gonza´lez et al., “Effect of charge
substitutions at residueHis-142 on voltage gating of connexin43
channels,” Biophysical Journal, vol. 91, no. 11, pp. 4054–4063,
2006.
[95] J. F. Ek, M. Delmar, R. Perzova, and S. M. Taffet, “Role of
histidine 95 on pH gating of the cardiac gap junction protein
connexin43,” Circulation Research, vol. 74, no. 6, pp. 1058–1064,
1994.
[96] N. Wang, M. De Bock, E. Decrock et al., “Connexin target-
ing peptides as inhibitors of voltage- and intracellular Ca2+-
triggered Cx43 hemichannel opening,” Neuropharmacology,
vol. 75, pp. 506–516, 2013.
[97] N. Wang, M. De Bock, G. Antoons et al., “Connexin mimetic
peptides inhibit Cx43 hemichannel opening triggered by volt-
age and intracellular Ca2+ elevation,” Basic Research in Cardiol-
ogy, vol. 107, article 304, 2012.
[98] E. De Vuyst, N. Wang, E. Decrock et al., “Ca2+ regulation of
connexin 43 hemichannels in C6 glioma and glial cells,” Cell
Calcium, vol. 46, no. 3, pp. 176–187, 2009.
[99] K. Shintani-Ishida, K. Uemura, and K.-I. Yoshida, “Hemichan-
nels in cardiomyocytes open transiently during ischemia and
contribute to reperfusion injury following brief ischemia,”
American Journal of Physiology—Heart and Circulatory Physi-
ology, vol. 293, no. 3, pp. H1714–H1720, 2007.
[100] R. Ponsaerts, E. De Vuyst, M. Retamal et al., “Intramolec-
ular loop/tail interactions are essential for connexin 43-
hemichannel activity,” The FASEB Journal, vol. 24, no. 11, pp.
4378–4395, 2010.
[101] R. Ponsaerts, C. D’hondt, F. Hertens et al., “RhoA GTPase
switch controls Cx43-hemichannel activity through the con-
tractile system,” PLoS ONE, vol. 7, no. 7, Article ID e42074, 2012.
[102] J. Iyyathurai, C. D’Hondt, N.Wang et al., “Peptides and peptide-
derived molecules targeting the intracellular domains of Cx43:
gap junctions versus hemichannels,” Neuropharmacology, vol.
75, pp. 491–505, 2013.
[103] M. M. Falk, “Cell-free synthesis for analyzing the membrane
integration, oligomerization, and assembly characteristics of
gap junction connexins,” Methods, vol. 20, no. 2, pp. 165–179,
2000.
[104] J. K. VanSlyke, C. C. Naus, and L. S. Musil, “Conformational
maturation and post-er multisubunit assembly of gap junction
proteins,”Molecular Biology of the Cell, vol. 20, no. 9, pp. 2451–
2463, 2009.
[105] G. Gaietta, T. J. Deerinck, S. R. Adams et al., “Multicolor and
electron microscopic imaging of connexin trafficking,” Science,
vol. 296, no. 5567, pp. 503–507, 2002.
[106] P. D. Lampe and A. F. Lau, “The effects of connexin phospho-
rylation on gap junctional communication,” The International
Journal of Biochemistry & Cell Biology, vol. 36, no. 7, pp. 1171–
1186, 2004.
[107] K.Maass, J. Shibayama, S. E. Chase, K.Willecke, andM.Delmar,
“C-terminal truncation of connexin43 changes number, size,
and localization of cardiac gap junction plaques,” Circulation
Research, vol. 101, no. 12, pp. 1283–1291, 2007.
[108] V. M. Unger, N. M. Kumar, N. B. Gilula, and M. Yeager,
“Three-dimensional structure of a recombinant gap junction
membrane channel,” Science, vol. 283, no. 5405, pp. 1176–1180,
1999.
[109] T.-C. Kang, D.-S. Kim, S.-E. Kwak et al., “Epileptogenic roles
of astroglial death and regeneration in the dentate gyrus of
experimental temporal lobe epilepsy,” Glia, vol. 54, no. 4, pp.
258–271, 2006.
[110] X.-Q. Gong, Q. Shao, S. Langlois, D. Bai, and D. W. Laird, “Dif-
ferential potency of dominant negative connexin43 mutants in
oculodentodigital dysplasia,” The Journal of Biological Chem-
istry, vol. 282, no. 26, pp. 19190–19202, 2007.
[111] A. Lai, D.-N. Le, W. A. Paznekas, W. D. Gifford, E. W. Jabs,
and A. C. Charles, “Oculodentodigital dysplasia connexin43
mutations result in non-functional connexin hemichannels and
gap junctions in C6 glioma cells,” Journal of Cell Science, vol. 119,
no. 3, pp. 532–541, 2006.
[112] J. M. Churko, Q. Shao, X.-Q. Gong et al., “Human dermal
fibroblasts derived from oculodentodigital dysplasia patients
suggest that patients may have wound-healing defects,”Human
Mutation, vol. 32, no. 4, pp. 456–466, 2011.
[113] H. M. Hong, J. J. Yang, J. C. Shieh, M. L. Lin, and S. Y. Li, “Novel
mutations in the connexin43 (GJA1) and GJA1 pseudogenemay
contribute to nonsyndromic hearing loss,”HumanGenetics, vol.
127, pp. 545–551, 2010.
[114] E. De Vuyst, E. Decrock, M. De Bock et al., “Connexin
hemichannels and gap junction channels are differentially
influenced by lipopolysaccharide and basic fibroblast growth
factor,” Molecular Biology of the Cell, vol. 18, no. 1, pp. 34–46,
2007.
[115] I. Lu¨bkemeier, R. P. Requardt, X. Lin et al., “Deletion of the
last five C-terminal amino acid residues of connexin43 leads
to lethal ventricular arrhythmias in mice without affecting cou-
pling via gap junction channels,” Basic Research in Cardiology,
vol. 108, article 348, 2013.
[116] M. G. Kozoriz, J. F. Bechberger, G. R. Bechberger et al.,
“The connexin43 C-terminal region mediates neuroprotection
during stroke,” Journal of Neuropathology and Experimental
Neurology, vol. 69, no. 2, pp. 196–206, 2010.
[117] G. E. Morley, S. M. Taffet, and M. Delmar, “Intramolecular
interactions mediate pH regulation of connexin43 channels,”
Biophysical Journal, vol. 70, no. 3, pp. 1294–1302, 1996.
[118] A. W. Hunter, R. J. Barker, C. Zhu, and R. G. Gourdie, “Zonula
occludens-1 alters connexin43 gap junction size and organiza-
tion by influencing channel accretion,”Molecular Biology of the
Cell, vol. 16, no. 12, pp. 5686–5698, 2005.
Mediators of Inflammation 15
[119] J. M. Rhett, J. Jourdan, and R. G. Gourdie, “Connexin 43
connexon to gap junction transition is regulated by zonula
occludens-1,” Molecular Biology of the Cell, vol. 22, no. 9, pp.
1516–1528, 2011.
[120] B. L. Soder, J. T. Propst, T. M. Brooks et al., “The con-
nexin43 carboxyl-terminal peptide ACT1 modulates the bio-
logical response to silicone implants,” Plastic and Reconstructive
Surgery, vol. 123, no. 5, pp. 1440–1451, 2009.
[121] G. S. Ghatnekar, C. L. Grek, D. G. Armstrong, S. C. Desai, and
R. G. Gourdie, “The effect of a connexin43-based Peptide on the
healing of chronic venous leg ulcers: a multicenter, randomized
trial,” Journal of Investigative Dermatology, vol. 135, pp. 289–298,
2015.
[122] C. L. Grek, G. M. Prasad, V. Viswanathan, D. G. Armstrong,
R. G. Gourdie, and G. S. Ghatnekar, “Topical administration
of a connexin43-based peptide augments healing of chronic
neuropathic diabetic foot ulcers: a multicenter, randomized
trial,” Wound Repair and Regeneration, vol. 23, no. 2, pp. 203–
212, 2015.
[123] K. Moore, G. Ghatnekar, R. G. Gourdie, and J. D. Potts, “Impact
of the controlled release of a connexin 43 peptide on corneal
wound closure in an STZ model of type I diabetes,” PLoS ONE,
vol. 9, no. 1, Article ID e86570, 2014.
[124] M. P. O’Quinn, J. A. Palatinus, B. S. Harris, K. W. Hewett,
and R. G. Gourdie, “A peptide mimetic of the connexin43 car-
boxyl terminus reduces gap junction remodeling and induced
arrhythmia following ventricular injury,” Circulation Research,
vol. 108, no. 6, pp. 704–715, 2011.
[125] C. L. Grek, J. M. Rhett, J. S. Bruce, M. A. Abt, G. S. Ghat-
nekar, and E. S. Yeh, “Targeting connexin 43 with 𝛼–connexin
carboxyl-terminal (ACT1) peptide enhances the activity of the
targeted inhibitors, tamoxifen and lapatinib, in breast cancer:
clinical implication for ACT1,” BMC Cancer, vol. 15, article 296,
2015.
[126] M. F. Santiago, P. Alcami, K. M. Striedinger, D. C. Spray, and
E. Scemes, “The carboxyl-terminal domain of connexin43 is
a negative modulator of neuronal differentiation,” Journal of
Biological Chemistry, vol. 285, no. 16, pp. 11836–11845, 2010.
[127] X. Dang, B. W. Doble, and E. Kardami, “The carboxy-tail of
connexin-43 localizes to the nucleus and inhibits cell growth,”
Molecular and Cellular Biochemistry, vol. 242, no. 1-2, pp. 35–38,
2003.
[128] C. Moorby and M. Patel, “Dual functions for connexins: Cx43
regulates growth independently of gap junction formation,”
Experimental Cell Research, vol. 271, no. 2, pp. 238–248, 2001.
[129] M. Vinken, E. Decrock, L. Leybaert et al., “Non-channel
functions of connexins in cell growth and cell death,”Biochimica
et Biophysica Acta—Biomembranes, vol. 1818, no. 8, pp. 2002–
2008, 2012.
[130] D. Johansen, V. Cruciani, R. Sundset, K. Ytrehus, and S.-O.
Mikalsen, “Ischemia induces closure of gap junctional channels
and opening of hemichannels in heart-derived cells and tissue,”
Cellular Physiology and Biochemistry, vol. 28, no. 1, pp. 103–114,
2011.
[131] R. Joshi-Mukherjee, W. Coombs, C. Burrer, I. Alvarez de Mora,
M. Delmar, and S. M. Taffet, “Evidence for the presence of
a free C-Terminal fragment of Cx43 in cultured cells,” Cell
Communication and Adhesion, vol. 14, no. 2-3, pp. 75–84, 2007.
[132] J. W. Smyth and R. M. Shaw, “Autoregulation of connexin43
gap junction formation by internally translated isoforms,” Cell
Reports, vol. 5, no. 3, pp. 611–618, 2013.
[133] C. Salat-Canela, M. Sese´, C. Peula, S. Ramo´n Y Cajal, and T.
Aasen, “Internal translation of the connexin 43 transcript,” Cell
Communication and Signaling, vol. 12, article 31, 2014.
[134] C. Salat-Canela, M. Mun˜oz, M. Sese´, S. Ramo´n y Cajal, and T.
Aasen, “Post-transcriptional regulation of connexins,”Biochem-
ical Society Transactions, vol. 43, no. 3, pp. 465–470, 2015.
[135] R. Schulz, P. M. Go¨rge, A. Go¨rbe, P. Ferdinandy, P. D. Lampe,
and L. Leybaert, “Connexin 43 is an emerging therapeutic
target in ischemia/reperfusion injury, cardioprotection and
neuroprotection,” Pharmacology & Therapeutics, vol. 153, pp.
90–106, 2015.
[136] G. Hawat, P. He´lie, and G. Baroudi, “Single intravenous
low-dose injections of connexin 43 mimetic peptides protect
ischemic heart in vivo against myocardial infarction,” Journal of
Molecular and Cellular Cardiology, vol. 53, no. 4, pp. 559–566,
2012.
[137] J. J. Yoon, C. R. Green, S. J. O’Carroll, and L. F. B. Nichol-
son, “Dose-dependent protective effect of connexin43 mimetic
peptide against neurodegeneration in an ex vivo model of
epileptiform lesion,” Epilepsy Research, vol. 92, no. 2-3, pp. 153–
162, 2010.
[138] Y.-S. Chen, I. Toth, H. V. Danesh-Meyer, C. R. Green, and I.
D. Rupenthal, “Cytotoxicity and vitreous stability of chemically
modified connexin43 mimetic peptides for the treatment of
optic neuropathy,” Journal of Pharmaceutical Sciences, vol. 102,
no. 7, pp. 2322–2331, 2013.
[139] J. A. Orellana, D. E. Herna´ndez, P. Ezan et al., “Hypoxia in
high glucose followed by reoxygenation in normal glucose
reduces the viability of cortical astrocytes through increased
permeability of connexin 43 hemichannels,” Glia, vol. 58, no. 3,
pp. 329–343, 2010.
[140] D. Umebayashi, A. Natsume, H. Takeuchi et al., “Blockade of
gap junction hemichannel protects secondary spinal cord injury
from activated microglia-mediated glutamate exitoneurotoxic-
ity,” Journal of Neurotrauma, vol. 31, no. 24, pp. 1967–1974, 2014.
[141] J. A. Orellana, K. F. Shoji, V. Abudara et al., “Amyloid 𝛽-induced
death in neurons involves glial and neuronal hemichannels,”
Journal of Neuroscience, vol. 31, no. 13, pp. 4962–4977, 2011.
[142] J. Shijie, H. Takeuchi, I. Yawata et al., “Blockade of glutamate
release from microglia attenuates experimental autoimmune
encephalomyelitis in mice,” Tohoku Journal of Experimental
Medicine, vol. 217, no. 2, pp. 87–92, 2009.
[143] C. Huang, X. Han, X. Li et al., “Critical role of connexin 43 in
secondary expansion of traumatic spinal cord injury,” Journal of
Neuroscience, vol. 32, no. 10, pp. 3333–3338, 2012.
[144] M. V. L. Bennett, J. M. Garre´, J. A. Orellana, F. F. Bukauskas,
M. Nedergaard, and J. C. Sa´ez, “Connexin and pannexin
hemichannels in inflammatory responses of glia and neurons,”
Brain Research, vol. 1487, pp. 3–15, 2012.
[145] S. B. Shaikh, B. Uy, A. Perera, and L. F. B. Nicholson, “AGEs-
RAGE mediated up-regulation of connexin43 in activated
human microglial CHME-5 cells,” Neurochemistry Interna-
tional, vol. 60, no. 6, pp. 640–651, 2012.
[146] M. A. Retamal, N. Froger, N. Palacios-Prado et al., “Cx43
hemichannels and gap junction channels in astrocytes are
regulated oppositely by proinflammatory cytokines released
from activated microglia,” The Journal of Neuroscience, vol. 27,
no. 50, pp. 13781–13792, 2007.
[147] M. Morita, C. Saruta, N. Kozuka et al., “Dual regulation of
astrocyte gap junction hemichannels by growth factors and a
pro-inflammatory cytokine via the mitogen-activated protein
kinase cascade,” Glia, vol. 55, no. 5, pp. 508–515, 2007.
16 Mediators of Inflammation
[148] J. Xiong, M. Burkovetskaya, N. Karpuk, and T. Kielian, “IL-1RI
(interleukin-1 receptor type I) signalling is essential for host
defence and hemichannel activity during acute central nervous
system bacterial infection,” ASN Neuro, vol. 4, no. 3, 2012.
[149] N. Wang, M. De Bock, E. Decrock et al., “Paracrine signaling
through plasma membrane hemichannels,” Biochimica et Bio-
physica Acta, vol. 1828, no. 1, pp. 35–50, 2013.
[150] G. Arcuino, J. H.-C. Lin, T. Takano et al., “Intercellular calcium
signaling mediated by point-source burst release of ATP,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 15, pp. 9840–9845, 2002.
[151] C. Lecut, K. Frederix, D. M. Johnson et al., “P2X1 ion channels
promote neutrophil chemotaxis throughRhokinase activation,”
Journal of Immunology, vol. 183, no. 4, pp. 2801–2809, 2009.
[152] Y. Sumi, T. Woehrle, Y. Chen et al., “Plasma ATP is required for
neutrophil activation in a mouse sepsis model,” Shock, vol. 42,
no. 2, pp. 142–147, 2014.
[153] N. Riteau, P. Gasse, L. Fauconnier et al., “Extracellular ATP is
a danger signal activating P2X7 receptor in lung inflammation
and fibrosis,” American Journal of Respiratory and Critical Care
Medicine, vol. 182, no. 6, pp. 774–783, 2010.
[154] Y. Chen, R. Corriden, Y. Inoue et al., “ATP release guides
neutrophil chemotaxis via P2Y2 and A3 receptors,” Science, vol.
314, no. 5806, pp. 1792–1795, 2006.
[155] B.W. Calder, J. M. Rhett, H. Bainbridge, S. A. Fann, R. G. Gour-
die, and M. J. Yost, “Inhibition of connexin 43 hemichannel-
mediated ATP release attenuates early inflammation during the
foreign body response,” Tissue Engineering Part A, vol. 21, no.
11-12, pp. 1752–1762, 2015.
[156] H. K. Eltzschig, T. Eckle, A. Mager et al., “ATP release from
activated neutrophils occurs via connexin 43 and modulates
adenosine-dependent endothelial cell function,” Circulation
Research, vol. 99, no. 10, pp. 1100–1108, 2006.
[157] H. K. Eltzschig, C. F. MacManus, and S. P. Colgan, “Neutrophils
as sources of extracellular nucleotides: functional consequences
at the vascular interface,” Trends in Cardiovascular Medicine,
vol. 18, no. 3, pp. 103–107, 2008.
[158] A. Gombault, L. Baron, and I. Couillin, “ATP release and
purinergic signaling in NLRP3 inflammasome activation,”
Frontiers in Immunology, vol. 3, article 414, 2012.
[159] J. Robertson, S. Lang, P. A. Lambert, and P. E. Martin, “Pep-
tidoglycan derived from Staphylococcus epidermidis induces
Connexin43 hemichannel activity with consequences on the
innate immune response in endothelial cells,” Biochemical
Journal, vol. 432, no. 1, pp. 133–143, 2010.
[160] G. Chen, C.-K. Park, R.-G. Xie, T. Berta,M.Nedergaard, andR.-
R. Ji, “Connexin-43 induces chemokine release from spinal cord
astrocytes to maintain late-phase neuropathic pain in mice,”
Brain, vol. 137, no. 8, pp. 2193–2209, 2014.
[161] J. Y. Lee, H. Y. Choi, and T. Y. Yune, “MMP-3 secreted
from endothelial cells of blood vessels after spinal cord injury
activates microglia, leading to oligodendrocyte cell death,”
Neurobiology of Disease, vol. 82, pp. 141–151, 2015.
[162] J. Y. Lee, H. Y. Choi, W. H. Na, B. G. Ju, and T. Y. Yune, “17𝛽-
estradiol inhibits MMP-9 and SUR1/TrpM4 expression and
activation and thereby attenuates BSCB disruption/hemorrhage
after spinal cord injury inmale rats,” Endocrinology, vol. 156, no.
5, pp. 1838–1850, 2015.
[163] B. Zinnhardt, T. Viel, L.Wachsmuth et al., “Multimodal imaging
reveals temporal and spatial microglia and matrix metallopro-
teinase activity after experimental stroke,” Journal of Cerebral
Blood Flow &Metabolism, 2015.
[164] E. Pollock, M. Everest, A. Brown, and M. O. Poulter, “Metal-
loproteinase inhibition prevents inhibitory synapse reorganiza-
tion and seizure genesis,” Neurobiology of Disease, vol. 70, pp.
21–31, 2014.
[165] H. Mizoguchi and K. Yamada, “Roles of matrix metallopro-
teinases and their targets in epileptogenesis and seizures,”
Clinical Psychopharmacology and Neuroscience, vol. 11, no. 2, pp.
45–52, 2013.
[166] X. Zhang, M. Cheng, and S. K. Chintala, “Optic nerve ligation
leads to astrocyte-associatedmatrixmetalloproteinase-9 induc-
tion in the mouse retina,” Neuroscience Letters, vol. 356, no. 2,
pp. 140–144, 2004.
[167] D. B. Corry, A. Kiss, L.-Z. Song et al., “Overlapping and
independent contributions of MMP2 and MMP9 to lung
allergic inflammatory cell egression through decreased CC
chemokines,” The FASEB Journal, vol. 18, no. 9, pp. 995–997,
2004.
[168] D. B. Corry, K. Rishi, J. Kanellis et al., “Decreased allergic
lung inflammatory cell egression and increased susceptibility to
asphyxiation in MMP2-deficiency,” Nature Immunology, vol. 3,
no. 4, pp. 347–353, 2002.
[169] K. B. Deatrick, C. E. Luke, M. A. Elfline et al., “The effect of
matrix metalloproteinase 2 and matrix metalloproteinase 2/9
deletion in experimental post-thrombotic vein wall remodel-
ing,” Journal of Vascular Surgery, vol. 58, no. 5, pp. 1375–e2, 2013.
[170] D. D. Cataldo, K. G. Tournoy, K. Vermaelen et al., “Matrix
metalloproteinase-9 deficiency impairs cellular infiltration and
bronchial hyperresponsiveness during allergen-induced airway
inflammation,”The American Journal of Pathology, vol. 161, no.
2, pp. 491–498, 2002.
[171] A. Luttun, E. Lutgens, A. Manderveld et al., “Loss of matrix
metalloproteinase-9 or matrix metalloproteinase-12 protects
apolipoprotein E-deficient mice against atherosclerotic media
destruction but differentially affects plaque growth,” Circula-
tion, vol. 109, no. 11, pp. 1408–1414, 2004.
[172] Q. Li, P. W. Park, C. L. Wilson, and W. C. Parks, “Matrilysin
shedding of syndecan-1 regulates chemokine mobilization and
transepithelial efflux of neutrophils in acute lung injury,” Cell,
vol. 111, no. 5, pp. 635–646, 2002.
[173] N. Mitsiades, W.-H. Yu, V. Poulaki, M. Tsokos, and I. Sta-
menkovic, “Matrix metalloproteinase-7-mediated cleavage of
Fas ligand protects tumor cells from chemotherapeutic drug
cytotoxicity,” Cancer Research, vol. 61, no. 2, pp. 577–581, 2001.
[174] W. Tian and T. R. Kyriakides, “Matrix metalloproteinase-9
deficiency leads to prolonged foreign body response in the brain
associated with increased IL-1beta levels and leakage of the
blood-brain barrier,”Matrix Biology, vol. 28, no. 3, pp. 148–159,
2009.
[175] S. J. McMillan, J. Kearley, J. D. Campbell et al., “Matrix
metalloproteinase-9 deficiency results in enhanced allergen-
induced airway inflammation,” Journal of Immunology, vol. 172,
no. 4, pp. 2586–2594, 2004.
[176] S. Lanone, T. Zheng, Z. Zhu et al., “Overlapping and enzyme-
specific contributions of matrix metalloproteinases-9 and -12
in IL-13-induced inflammation and remodeling,”The Journal of
Clinical Investigation, vol. 110, no. 4, pp. 463–474, 2002.
[177] P. J. Sa´ez, K. F. Shoji, M. A. Retamal et al., “ATP is required and
advances cytokine-induced gap junction formation inmicroglia
in vitro,” Mediators of Inflammation, vol. 2013, Article ID
216402, 16 pages, 2013.
Mediators of Inflammation 17
[178] N. Froger, J. A. Orellana, C.-F. Calvo et al., “Inhibition of
cytokine-induced connexin43 hemichannel activity in astro-
cytes is neuroprotective,” Molecular and Cellular Neuroscience,
vol. 45, no. 1, pp. 37–46, 2010.
[179] C.-Y. Wu, H.-L. Hsieh, C.-C. Sun, and C.-M. Yang, “IL-
1𝛽 induces MMP-9 expression via a Ca2+-dependent
CaMKII/JNK/c-Jun cascade in rat brain astrocytes,” Glia,
vol. 57, no. 16, pp. 1775–1789, 2009.
[180] B. J. Hirst-Jensen, P. Sahoo, F. Kieken, M. Delmar, and P.
L. Sorgen, “Characterization of the pH-dependent interaction
between the gap junction protein connexin43 carboxyl ter-
minus and cytoplasmic loop domains,” Journal of Biological
Chemistry, vol. 282, no. 8, pp. 5801–5813, 2007.
[181] F. Liu, F. T. Arce, S. Ramachandran, andR. Lal, “Nanomechanics
of hemichannel conformations: connexin flexibility underlying
channel opening and closing,” Journal of Biological Chemistry,
vol. 281, no. 32, pp. 23207–23217, 2006.
[182] E. Butkevich, S. Hu¨lsmann, D.Wenzel, T. Shirao, R. Duden, and
I. Majoul, “Drebrin is a novel connexin-43 binding partner that
links gap junctions to the submembrane cytoskeleton,” Current
Biology, vol. 14, no. 8, pp. 650–658, 2004.
[183] M. L. Vitale, C. D. Akpovi, and R.-M. Pelletier,
“Cortactin/tyrosine-phosphorylated cortactin interaction
with connexin 43 in mouse seminiferous tubules,” Microscopy
Research and Technique, vol. 72, no. 11, pp. 856–867, 2009.
[184] G. Pidoux, P. Gerbaud, J. Dompierre et al., “A PKA-ezrin-Cx43
signaling complex controls gap junction communication and
thereby trophoblast cell fusion,” Journal of Cell Science, vol. 127,
no. 19, pp. 4172–4185, 2014.
[185] P. L. Sorgen, H. S. Duffy, P. Sahoo, W. Coombs, M. Delmar, and
D. C. Spray, “Structural changes in the carboxyl terminus of the
gap junction protein connexin43 indicates signaling between
binding domains for c-Src and zonula occludens-1,”The Journal
of Biological Chemistry, vol. 279, no. 52, pp. 54695–54701, 2004.
[186] Z. Lan, W. E. Kurata, K. D. Martyn, C. Jin, and A. F. Lau, “Novel
Rab GAP-like protein, CIP85, interacts with connexin43 and
induces its degradation,” Biochemistry, vol. 44, no. 7, pp. 2385–
2396, 2005.
[187] C. S. Wun, J. F. Bechberger, W. J. Rushlow, and C. C. Naus,
“Dose-dependent differential upregulation of CCN1/Cyr61 and
CCN3/NOV by the gap junction protein connexin43 in glioma
cells,” Journal of Cellular Biochemistry, vol. 103, no. 6, pp. 1772–
1782, 2008.
[188] B. N. G. Giepmans and W. H. Moolenaar, “The gap junction
protein connexin43 interacts with the second PDZ domain of
the zona occludens-1 protein,”Current Biology, vol. 8, no. 16, pp.
931–934, 1998.
[189] R. Ponsaerts, N. Wang, B. Himpens, L. Leybaert, and G.
Bultynck, “The contractile system as a negative regulator of the
connexin 43 hemichannel,” Biology of the Cell, vol. 104, no. 7, pp.
367–377, 2012.
[190] G. Ermak and K. J. A. Davies, “Calcium and oxidative stress:
from cell signaling to cell death,” Molecular Immunology, vol.
38, no. 10, pp. 713–721, 2002.
[191] S. Ramachandra, L.-H. Xie, S. A. John, S. Subramaniam, and
R. Lal, “A novel role for connexin hemichannel in oxidative
stress and smoking-induced cell injury,” PLoS ONE, vol. 2, no.
8, article e712, 2007.
[192] R. Kar, M. A. Riquelme, S. Werner, and J. X. Jiang, “Connexin
43 channels protect osteocytes against oxidative stress-induced
cell death,” Journal of Bone and Mineral Research, vol. 28, no. 7,
pp. 1611–1621, 2013.
[193] P. P. Cherian, A. J. Siller-Jackson, S. Gu et al., “Mechanical
strain opens connexin 43 hemichannels in osteocytes: a novel
mechanism for the release of prostaglandin,”Molecular Biology
of the Cell, vol. 16, no. 7, pp. 3100–3106, 2005.
[194] L. I. Plotkin, S. C. Manolagas, and T. Bellido, “Transduction of
cell survival signals by connexin-43 hemichannels,”The Journal
of Biological Chemistry, vol. 277, no. 10, pp. 8648–8657, 2002.
[195] D. E. Lee, B. J. Shin, H. J. Hur et al., “Quercetin, the active
phenolic component in kiwifruit, prevents hydrogen peroxide-
induced inhibition of gap-junction intercellular communica-
tion,” British Journal of Nutrition, vol. 104, no. 2, pp. 164–170,
2010.
[196] A. A. Sovari, C. A. Rutledge, E.-M. Jeong et al., “Mitochondria
oxidative stress, connexin43 remodeling, and sudden arrhyth-
mic death,” Circulation: Arrhythmia and Electrophysiology, vol.
6, no. 3, pp. 623–631, 2013.
[197] G. R. John, E. Scemes, S. O. Suadicani et al., “IL-1𝛽 differentially
regulates calcium wave propagation between primary human
fetal astrocytes via pathways involving P2 receptors and gap
junction channels,” Proceedings of the National Academy of
Sciences of theUnited States of America, vol. 96, no. 20, pp. 11613–
11618, 1999.
[198] H. S. Duffy, G. R. John, S. C. Lee, C. F. Brosnan, and D. C.
Spray, “Reciprocal regulation of the junctional proteins claudin-
1 and connexin43 by interleukin-1beta in primary human fetal
astrocytes,” The Journal of Neuroscience, vol. 20, Article ID
RC114, 2000.
[199] W. Meˆme, P. Ezan, L. Venance, J. Glowinski, and C. Giaume,
“ATP-induced inhibition of gap junctional communication is
enhanced by interleukin-1 beta treatment in cultured astro-
cytes,” Neuroscience, vol. 126, no. 1, pp. 95–104, 2004.
[200] P. Castellano and E. A. Eugenin, “Regulation of gap junction
channels by infectious agents and inflammation in the CNS,”
Frontiers in Cellular Neuroscience, vol. 8, article 122, 2014.
[201] C. A. Kasper, I. Sorg, C. Schmutz et al., “Cell-cell propagation
of NF-kappaB transcription factor and MAP kinase activation
amplifies innate immunity against bacterial infection,” Immu-
nity, vol. 33, no. 5, pp. 804–816, 2010.
[202] E. A. Eugenı´n,M. C. Bran˜es, J.W. Berman, and J. C. Sa´ez, “TNF-
𝛼𝛼 plus IFN-𝛾 induce connexin43 expression and formation
of gap junctions between human monocytes/macrophages that
enhance physiological responses,” Journal of Immunology, vol.
170, no. 3, pp. 1320–1328, 2003.
[203] I. Feine, I. Pinkas, Y. Salomon, and A. Scherz, “Local oxidative
stress expansion through endothelial cells—a key role for gap
junction intercellular communication,” PLoS ONE, vol. 7, no. 7,
Article ID e41633, 2012.
[204] J. Neijssen, C. Herberts, J. W. Drijfhout, E. Reits, L. Janssen, and
J. Neefjes, “Cross-presentation by intercellular peptide transfer
through gap junctions,” Nature, vol. 434, no. 7029, pp. 83–88,
2005.
[205] J.-C. Herve´, N. Bourmeyster, D. Sarrouilhe, and H. S. Duffy,
“Gap junctional complexes: from partners to functions,”
Progress in Biophysics andMolecular Biology, vol. 94, no. 1-2, pp.
29–65, 2007.
[206] A. Tabernero, E. Gangoso, M. Jara´ız-Rodr´ıguez, and J. Medina,
“The role of connexin43–Src interaction in astrocytomas: a
molecular puzzle,” Neuroscience, 2015.
[207] E. Scemes, N. Duval, and P.Meda, “Reduced expression of P2Y
1
receptors in connexin43-null mice alters calcium signaling and
migration of neural progenitor cells,” Journal of Neuroscience,
vol. 23, no. 36, pp. 11444–11452, 2003.
18 Mediators of Inflammation
[208] E. Scemes, “Modulation of astrocyte P2Y1 receptors by the
carboxyl terminal domain of the gap junction protein Cx43,”
Glia, vol. 56, no. 2, pp. 145–153, 2008.
[209] M. W. M. Li, D. D. Mruk, and C. Y. Cheng, “Gap junctions and
blood-tissue barriers,” Advances in Experimental Medicine and
Biology, vol. 763, pp. 260–280, 2013.
[210] M.W.M. Li,D.D.Mruk,W.M. Lee, andC.Y.Cheng, “Connexin
43 is critical to maintain the homeostasis of the blood-testis
barrier via its effects on tight junction reassembly,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 107, no. 42, pp. 17998–18003, 2010.
[211] H. Morita, T. Katsuno, A. Hoshimoto, N. Hirano, Y. Saito,
and Y. Suzuki, “Connexin 26-mediated gap junctional inter-
cellular communication suppresses paracellular permeability of
human intestinal epithelial cell monolayers,” Experimental Cell
Research, vol. 298, no. 1, pp. 1–8, 2004.
[212] T. Kojima, M. Murata, M. Go, D. C. Spray, and N. Sawada,
“Connexins induce and maintain tight junctions in epithelial
cells,” Journal of Membrane Biology, vol. 217, no. 1–3, pp. 13–19,
2007.
[213] J.-C. Wu, R.-Y. Tsai, and T.-H. Chung, “Role of catenins in the
development of gap junctions in rat cardiomyocytes,” Journal of
Cellular Biochemistry, vol. 88, no. 4, pp. 823–835, 2003.
[214] C.-J. Wei, R. Francis, X. Xu, and C. W. Lo, “Connexin43 asso-
ciated with an N-cadherin-containing multiprotein complex
is required for gap junction formation in NIH
3
T
3
cells,” The
Journal of Biological Chemistry, vol. 280, no. 20, pp. 19925–
19936, 2005.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
